Tumor eradication by inositol-tripyrophosphate

The present invention relates to various salts of inositol tripyrophosphate including the calcium, lithium, beryllium, magnesium, potassium, strontium, barium, rubidium and cesium salts of inositol tripyrophosphate, compositions comprising these salts, methods of making the various salts, and methods of use of the above salts. Methods of use include administering the above salts in an effective amount in individuals for the treatment of various types of cancers, Alzheimer's disease, stroke and osteoporosis.

Phosphorylcholine-based amphiphilic silicones for medical applications

Amphiphilic biomimetic phosphorylcholine-containing silicone compounds for use in both topical and internal applications as components in biomedical devices. The silicone compounds, which include zwitterionic phosphorylcholine groups, may be polymerizable or non-polymerizable. Specific examples of applications include use as active functional components in ophthalmic lenses, ophthalmic lens care solutions, liquid bandages, wound dressings, and lubricious and anti-thrombogenic coatings.

Bis-phosphate compound and asymmetric reaction using the same

A novel bis-phosphate compound is provided which can be applied to a wide range of reactive substrates and reactions as an asymmetric reaction catalyst and can realize an asymmetric reaction affording a high yield and a high enantiomeric excess. The bis-phosphate compound has a tetraaryl skeleton represented by General Formula (1). In an asymmetric reaction, an amidodiene and an unsaturated aldehyde compound are reacted with each other in the presence of the optically active bis-phosphate compound to give an optically active amidoaldehyde. The invention allows a reaction such as an asymmetric Diels-Alder reaction to proceed efficiently, which has been difficult with conventional mono-phosphate compounds. Thus, the invention enables an industrially feasible method for the production of optically active amidoaldehydes, optically active β-amino acid derivatives, optically active diamine compounds, optically active pyrrolidine derivatives and optically active dihydropyran derivatives which are useful as products such as medicines, agricultural chemicals and chemical products as well as synthesis intermediates for such products.

Non-aqueous electrolyte additive for lithium secondary battery, non-aqueous electrolyte, and lithium secondary battery including the same

A non-aqueous electrolyte additive for a lithium secondary battery, a non-aqueous electrolyte for a lithium secondary battery, and a lithium secondary battery, the additive including a bidentate phosphorus compound represented by the following Chemical Formula 1.

Organophosphorus compounds, catalytic systems comprising said compounds and method of hydrocyanation using said catalytic systems

The present invention relates to organophosphorus compounds belonging to the phosphinite-phosphite family, catalytic systems comprising a metallic element forming a complex with said phosphinite-phosphite compounds and methods of hydrocyanation employed in the presence of said catalytic systems.

BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF

Bisphosphonamidate prodrugs of therapeutic bisphosphonate compounds and uses thereof to treat diseases are described. 2. The compound of claim 1 , where Ris hydrogen claim 1 , alkyl claim 1 , halogen claim 1 , aminoalkyl claim 1 , thioaryl claim 1 , or heteroalkyl.3. The compound of claim 1 , where Ris H claim 1 , halogen claim 1 , or hydroxyl.4. The compound of claim 1 , where Rand Rare H.5. The compound of claim 1 , where Rand Rare Cl.6. The compound of claim 1 , where Ris heteroaralkyl or aminoalkyl claim 1 , and Ris hydroxyl.7. The compound of claim 1 , where Ris alkyl.8. The compound of claim 1 , where Ris alkyl or aralkyl.9. The compound of claim 1 , where X is Cl.11. The compound of claim 10 , where Ror Rare hydrogen or nitro.12. The compound of claim 10 , where A is —C═C—.13. The compound of claim 10 , where Ris hydrogen claim 10 , alkyl claim 10 , halogen claim 10 , aminoalkyl claim 10 , thioaryl claim 10 , heteroaralkyl.14. The compound of claim 10 , where Ris H claim 10 , halogen claim 10 , or hydroxyl.15. The compound of claim 10 , where Rand Rare H.16. The compound of claim 10 , where Rand Rare Cl.17. The compound of claim 10 , where Ris heteroaralkyl or aminoalkyl claim 10 , and Ris hydroxyl.18. The compound of claim 10 , where Ris alkyl.19. The compound of claim 10 , where X is Cl.21. The compound of claim 20 , where Ris nitro and Ris H or R.22. The compound of claim 20 , where Ris hydrogen claim 20 , alkyl claim 20 , halogen claim 20 , aminoalkyl claim 20 , thioaryl claim 20 , heteroaralkyl.23. The compound of claim 20 , where Ris H claim 20 , halogen claim 20 , or hydroxyl.24. The compound of claim 20 , where Rand Rare H.25. The compound of claim 20 , where Rand Rare Cl.26. The compound of claim 20 , where Ris heteroaralkyl or aminoalkyl claim 20 , and Ris hydroxyl.27. The compound of claim 20 , where Ris alkyl.28. The compound of claim 20 , where A is —C═C—.29. The compound of claim 20 , where X is Cl.31. The compound of claim 30 , where Ris nitro ...

PHOSPHORUS-CONTAINING OLIGOMER AND METHOD FOR PRODUCING THE SAME, CURABLE RESIN COMPOSITION AND CURED PRODUCT OF THE SAME, AND PRINTED WIRING BOARD

A phosphorus-containing oligomer is represented by formula (1): 13-. (canceled)57-. (canceled) The present invention relates to a phosphorus containing oligomer that has high solubility in a solvent and exhibits high flame retardancy and heat resistance in the form of a cured product thereof, a method for producing the phosphorus-containing oligomer, a curable resin composition that uses the oligomer as a curing agent for epoxy resins, a cured product of the curable resin composition, and a printed wiring board that uses the curable resin composition.Epoxy resins and epoxy resin compositions containing a curing agent for epoxy resins as an essential component have excellent physical properties such as high heat resistance and moisture resistance and hence are widely used for, for example, semiconductor sealing materials, electronic components such as printed circuit boards, the electronic component field, conductive adhesives such as conductive pastes, other adhesives, matrices for composite materials, coating materials, photoresist materials, and development materials.In recent years, further enhancement of properties such as heat resistance, moisture resistance, and solder resistance has been demanded in such various applications, in particular, applications to advanced materials. In vehicle-mounted electronic devices that are particularly required to have high reliability, the installation position has been changed from a cabin to an engine compartment having a higher temperature than a cabin. In addition, reflowing treatment temperature has increased due to use of lead-free solder. Therefore, high heat resistant materials that have higher glass transition temperature and can endure a thermal delamination test (hereinafter, abbreviated as “T288 test”) have been demanded.When epoxy resin compositions are used as materials for printed wiring boards, a flame retardant containing halogen such as bromine is added together with an antimony compound to impart flame ...

METHOD FOR THE PURIFICATION OF BIPHEPHOS

The invention relates to a process for the purification of 6,6′-[(3,3′-di-tert-butyl-5,5′-dimethoxy-1,1′-biphenyl-2,2′diyl)bis(oxy)]bis(dibenzo[d,f][1,3,2]dioxaphosphepin), abbreviation: biphephos (see formula 1). 1. A process for purifying biphephos , the process comprising:washing out the biphephos with at least one solvent selected from the group consisting of ethyl acetate, anisole, ortho-xylene, toluene, acetone, 2-propanol and C5-C10-alkane,recrystallizing the biphephos from the solvent, or both.2. The process according to claim 1 , wherein the solvent is acetonitrile-free.3. The process according to claim 1 , further comprising removing acetonitrile from the solvent.4. The process according to claim 1 , further comprising:dissolving the biphephos in the solvent,removing insoluble constituents by filtration,precipitating out or crystallizing out the biphephos, and by cooling the solventoptionally precipitating out or crystallizing out further biphephos by adding a C5-C10-alkane.5. The process according to claim 4 , wherein the solvent has a temperature of more than 50° C. and the insoluble constituents are removed by hot filtration.6. The process according to claim 1 , wherein the biphephos before the recrystallizing has a total chlorine content of up to 5000 ppm and after the recrystallizing has a total chlorine content of less than 500 ppm.7. The process according to claim 1 , comprising recrystallizing the biphephos from the solvent claim 1 ,wherein the solvent comprises up to 20% by weight of n-heptane and at least 50% by weight of ortho-xylene.8. The process according to claim 1 , comprising recrystallizing the biphephos from the solvent claim 1 ,wherein the solvent comprises up to 10% by weight of n-heptane and at least 90% by weight of ethyl acetate.9. The process according to claim 1 , further comprising claim 1 , after the recrystallizing claim 1 , isolating the biphephos claim 1 , and claim 1 , optionally claim 1 , drying the biphephos.10. (canceled) ...

PROCESSES FOR PRODUCING ORGANOPHOSPHOROUS COMPOUNDS

The present invention relates to processes for producing organophosporous compositions having low acid content as well as processes for reprocessing partially degraded organophosporous compositions that contain high levels of phosphorous acid. In one embodiment, a process comprises: (a) receiving a solid organophosphite compound that has been recrystallized or triturated, wherein the solid organophosphite compound comprises phosphorous acid; (b) dissolving the solid organophosphite compound in a an aromatic hydrocarbon solvent in the absence of water and free amine, wherein the hydrocarbon solvent comprises an aromatic hydrocarbon, a saturated aliphatic hydrocarbon, or a mixture thereof; and (c) removing undissolved phosphorous acid from the solution, wherein the acid content of the organophosphite following step (c) is 30 ppm or less. 1. A process comprising: (a) receiving a solid organophosphite compound that has been recrystallized or triturated , wherein the solid organophosphite compound comprises phosphorous acid; (b) dissolving the solid organophosphite compound in a hydrocarbon solvent , wherein the hydrocarbon solvent comprises an aromatic hydrocarbon , a saturated aliphatic hydrocarbon , or a mixture thereof; and (c) removing undissolved phosphorous acid from the solution , wherein the acid content of the organophosphite following step (c) is 30 ppm or less.2. The process of claim 1 , wherein the undissolved phosphorous acid is removed by filtration.3. The process of claim 1 , wherein the undissolved phosphorous acid is removed by centrifugation.4. The process of claim 1 , wherein the acid content of the organophosphite following step (c) is 10 ppm or less.5. The process of claim 1 , wherein the acid content of the organophosphite following step(c) is 5 ppm or less.6. The process of claim 1 , further comprising (d) concentrating the organophosphite in hydrocarbon solution; (e) combining the concentrated organophosphite in hydrocarbon solution with an anti- ...

PROCESSES FOR PRODUCING ORGANOPHOSPHOROUS COMPOUNDS

The present invention relates to processes for producing organophosporous compositions having low acid content as well as processes for reprocessing partially degraded organophosporous compositions that contain high levels of phosphorous acid. In one embodiment, a process comprises: (a) receiving a solid organophosphite compound that has been recrystallized or triturated, wherein the solid organophosphite compound comprises phosphorous acid; (b) dissolving the solid organophosphite compound in an organic solvent; (c) treating the solution with a weakly basic adsorbent; and (d) collecting the treated organophosphite solution, wherein the acid content of the organophosphite following step (d) is 30 ppm or less. 1. A process comprising: (a) receiving a solid organophosphite compound that has been recrystallized or triturated , wherein the solid organophosphite compound comprises phosphorous acid; (b) dissolving the solid organophosphite compound in an organic solvent; and (c) treating the solution with a weakly basic adsorbent; and (d) collecting the treated organophosphite solution , wherein the acid content of the organophosphite following step (d) is 30 ppm or less.2. The process of claim 1 , wherein the weakly basic adsorbent comprises a metal oxide claim 1 , a metal carbonate claim 1 , or an anionic clay having an effective pKa of less than 12 or a weakly basic ion exchange resin.3. The process of claim 2 , wherein the weakly basic adsorbent comprises a weakly basic ion exchange resin claim 2 , and the weakly basic ion exchange resin comprises at least 10 equivalents of a basic moiety per mole of acid in the organophosphite solution.4. The process of claim 1 , wherein the solid organophosphite compound is dissolved in the organic solvent in the absence of free amine.5. The process of claim 1 , wherein the solvent comprises toluene claim 1 , xylenes claim 1 , diethyl ether claim 1 , dichloromethane claim 1 , ethyl acetate claim 1 , butyraldehyde claim 1 , ...

Novel Compounds

A compound of Formula (I) 2. The method of wherein the cancer is melanoma.3. The method of wherein the cancer is head and neck cancer.4. The method of wherein the compound is administered by intratumoral injection.5. The method of wherein the compound is administered by peritumoral injection.6. The method of wherein the cancer is squamous cell carcinomas.7. The method of wherein the cancer is breast cancer.8. The method of wherein the compound is administered by intratumoral injection.9. The method of wherein the compound is administered by peritumoral injection.10. The method of wherein the cancer is hepatocellular cancer.11. The method of wherein the cancer is colon cancer.12. The method of wherein the cancer is esophageal cancer.13. The method of wherein the cancer is rectal cancer.14. The method of wherein the cancer is lung cancer.15. The method of wherein the compound is administered by intratumoral injection.16. The method of wherein the compound is administered by peritumoral injection.17. The method of wherein the cancer is renal cell cancer.18. The method of wherein claim 1 , the cancer is selected from: melanoma claim 1 , squamous cell carcinomas claim 1 , hepatocellular cancer claim 1 , colon cancer claim 1 , esophageal cancer claim 1 , rectal cancer claim 1 , and renal cell cancer claim 1 , and the compound is administered by intratumoral injection.19. The method of claim 1 , the wherein claim 1 , the cancer is selected from: melanoma claim 1 , squamous cell carcinomas claim 1 , hepatocellular cancer claim 1 , colon cancer claim 1 , esophageal cancer claim 1 , rectal cancer claim 1 , and renal cell cancer claim 1 , and the compound is administered by peritumoral injection.20. The method of wherein the cancer is selected from: brain (gliomas) claim 1 , glioblastomas claim 1 , astrocytomas claim 1 , glioblastoma multiforme claim 1 , Bannayan-Zonana syndrome claim 1 , Cowden disease claim 1 , Lhermitte-Duclos disease claim 1 , Wilm's tumor claim 1 , Ewing' ...

SYNTHESIS OF POLYPHOSPHORYLATED MOLECULES FROM POLYPHOSPHATES

Metaphosphate compounds can directly phosphorylate other compounds to provide easy synthetic access to phosphorylated compounds, including cyclic phosphate compounds. 1. A method of polyphosphorylating a compound comprising contacting the compound with an activated polyphosphate , wherein the compound includes a nucleophilic group.2. The method of claim 1 , wherein the activated polyphosphate is a triphosphate or a tetraphosphate claim 1 , optionally claim 1 , a cyclic phosphate.3. The method of claim 1 , wherein the activated polyphosphate is an N-oxy-amino polyphosphate ester.4. The method of claim 1 , wherein the activated polyphosphate is a trimetaphosphate 7-azabenzotriazole phosphoester or a trimetaphosphate benzotriazol-1-yl-oxy phosphoester or tetraphosphorylating agent anhydride [PO].5. The method of claim 1 , wherein the compound is HNuc claim 1 , wherein −Nuc includes an oxo claim 1 , amino claim 1 , or thio group.6. The method of claim 1 , wherein the compound is monohydrogen tetrametaphosphate.7. The method of claim 1 , wherein the activated polyphosphate is a phosphorus ylide.8. A compound comprising a triphosphorylated or tetraphosphorylated compound claim 1 , wherein the triphosphorylated or tetraphosphorlyated compound includes a cyclic phosphate.9. A compound comprising a trimetaphosphate 7-azabenzotriazole phosphoester claim 1 , a trimetaphosphate benzotriazol-1-yl-oxy phosphoester or tetraphosphorylating agent anhydride [PO].10. A method of polyphosphorylating a compound comprising contacting monohydrogen tetrametaphosphate with a protein coupling agent to form an activated polyphosphate and contacting the activated polyphosphate with the compound.11. The method of claim 10 , wherein the protein coupling agent is PyAOP claim 10 , PyBOP claim 10 , PyBrOP claim 10 , PyOxim claim 10 , or HATU.12. The method of claim 1 , wherein the compound is a biochemical substrate claim 1 , including a nucleoside claim 1 , an amino acid claim 1 , a sugar claim 1 ...

PHOSPHAPHENANTHRENE-BASED COMPOUND AND RELATED PREPARATION METHOD AND APPLICATION

Provided is a phosphaphenanthrene-based compound represented by the following chemical structure: 2. The phosphaphenanthrene-based compound according to claim 1 , wherein R and R′ are each independently a vinyl- and carbonyl-substituted alkyl group with 3 to 20 carbon atoms claim 1 , a vinyl- and carbonyl-substituted cycloalkyl group with 8 to 20 carbon atoms claim 1 , a vinyl- and carbonyl-substituted benzyl group with 9 to 20 carbon atoms or a vinyl- and carbonyl-substituted aromatic group with 8 to 20 carbon atoms.3. The phosphaphenanthrene-based compound according to claim 1 , wherein R and R′ are each independently a vinyl-substituted alkyl group with 3 to 20 carbon atoms claim 1 , or a vinyl-substituted benzyl group with 9 to 20 carbon atoms.9. The method of manufacturing a phosphaphenanthrene-based compound according to claim 8 , wherein the dialdehyde compound is at least one selected from the group consisting of the following: 1 claim 8 ,4-phthalaldehyde claim 8 ,1 claim 8 ,3-phthalaldehyde claim 8 ,1 claim 8 ,2-phthalaldehyde claim 8 , 2 claim 8 ,3-naphthalenedicarboxaldehyde claim 8 , 1 claim 8 ,6-naphthalenedicarboxaldehyde claim 8 , 1 claim 8 ,8-naphthalenedicarboxaldehyde claim 8 , 1 claim 8 ,7-naphthalenedicarboxaldehyde claim 8 , 4 claim 8 ,4′-biphenyldicarboxaldehyde claim 8 , 4 claim 8 ,4′-xenygloxal claim 8 , bisphenol A based dialdehyde claim 8 , bisphenol F based dialdehyde claim 8 , and bisphenol E based dialdehyde.10. The method of manufacturing a phosphaphenanthrene-based compound according to claim 8 , wherein a mole ratio of the 9 claim 8 ,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide and the dialdehyde compound ranges from 2:1 to 4:1.11. A resin composition comprising the phosphaphenanthrene-based compound according to .12. The resin composition according to claim 11 , wherein the resin composition comprises a reactant claim 11 , an amount of the reactant is 100 parts by weight claim 11 , an amount of the phosphaphenanthrene-based ...

6,6'-([1,1'-BIPHENYL]-2,3'-DIYLBIS(OXY))DIDIBENZO[D,F][1,3,2]DIOXAPHOSPHEPINES

6,6′-([1,1′-Biphenyl]-2,3′,-diylbis)oxy))didibenzo[d,f][1,3,2]dioxaphosphepines and the use thereof in hydroformylation. 2. Compound according to claim 1 , where R claim 1 , R claim 1 , R claim 1 , Rare selected from: —H claim 1 , —(C-C) alkyl.3. Compound according to claim 1 , where at least one of the radicals R claim 1 , R claim 1 , R claim 1 , Ris —H.4. Compound according to claim 1 , where R claim 1 , R claim 1 , R claim 1 , Rare —H.5. Compound according to claim 1 , where R claim 1 , R claim 1 , R claim 1 , Rare selected from: —H claim 1 , —O—(C-C) alkyl.6. Compound according to claim 1 , where at least one of the radicals R claim 1 , R claim 1 , R claim 1 , Ris —H.7. Compound according to claim 1 , where R claim 1 , R claim 1 , R claim 1 , Rare —H.9. Use of a compound according to in a ligand-metal complex for catalysis of a hydroformylation reaction.10. Process comprising the process steps of:a) initially charging an olefin,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'b) adding a compound according to and a substance containing a metal selected from: Rh, Ru, Co, Ir,'}{'sub': '2', 'c) feeding in Hand CO,'}d) heating the reaction mixture from steps a) to c), with conversion of the olefin to an aldehyde. The invention relates to 6,6′-([1,1′-biphenyl]-2,3′-diylbis(oxy))didibenzo[d,f][1,3,2]dioxaphosphepines and to the use thereof in hydroformylation.Phosphorus-containing compounds play a crucial role as ligands in a multitude of reactions, e.g. in hydrogenation, in hydrocyanation and also in hydroformylation.The reactions between olefin compounds, carbon monoxide and hydrogen in the presence of a catalyst to give the aldehydes with one carbon atom more are known as hydroformylation or the oxo process. Catalysts used in these reactions are frequently compounds of the transition metals of group VIII of the periodic table of the elements. Known ligands are, for example, compounds from the phosphine, phosphite and phosphonite classes, each containing trivalent ...

NEW DIPHOSPHITES BASED ON CIS-BUTENE-1,4-DIOL

New diphosphites based on cis-butene-1,4-diol. 2. Compound according to claim 1 ,{'sup': ['1', '4', '5', '8'], 'sub': ['1', '12'], '#text': 'where R, R, R, Rare selected from: —H, —(C-C) alkyl.'}3. Compound according to claim 1 ,{'sup': ['1', '4', '5', '8', 'l'], '#text': 'where the radicals R, R, R, Rare not all simultaneously —Bu.'}4. Compound according to claim 1 ,{'sup': ['1', '4', '5', '8', 'l'], '#text': 'where the radicals R, R, R, Rare not —Bu.'}5. Compound according to claim 1 ,{'sup': ['1', '4', '5', '8'], '#text': 'where at least one of the radicals R, R, R, Ris —H.'}6. Compound according to claim 1 ,{'sup': ['2', '3', '6', '7'], 'sub': ['1', '12'], '#text': 'where R, R, R, Rare selected from: —H, —O—(C-C) alkyl.'}7. Compound according to claim 1 ,{'sup': ['2', '3', '6', '7'], '#text': 'where at least one of the radicals R, R, R, Ris —H.'}8. Compound according to claim 1 ,where the compound has the structure (I).10. Compound according to claim 1 ,where the compound has the structure (II).12. Use of a compound according to in a ligand-metal complex for catalysis of a hydroformylation reaction.13. Process comprising the process steps of:a) initially charging an olefin,{'claim-ref': {'@idref': 'CLM-00001', '#text': 'claim 1'}, '#text': 'b) adding a compound according to and a substance containing a metal selected from: Rh, Ru, Co, Ir,'}{'sub': '2', '#text': 'c) feeding in Hand CO,'}d) heating the reaction mixture from steps a) to c), with conversion of the olefin to an aldehyde. The invention relates to new diphosphites based on cis-butene-1,4-diol.Phosphorus-containing compounds play a crucial role as ligands in a multitude of reactions, e.g. in hydrogenation, in hydrocyanation and also in hydroformylation.The reactions between olefin compounds, carbon monoxide and hydrogen in the presence of a catalyst to give the aldehydes with one carbon atom more are known as hydroformylation or the oxo process. Catalysts used in these reactions are frequently compounds ...

FLAME RETARDANTS FROM RENEWABLE RESOURCES

Among other things the invention provides novel flame-retardant compounds useful for increasing the flame retardance of polymers. 2. A compound according to claim 1 , wherein A contains from 2 to 20 member atoms.3. A compound according claim 1 , wherein A contains 1-5 heteroatoms.4. A compound according to claim 1 , wherein -A-X is (CRR)—X claim 1 , wherein each Rand Ris independently selected from the group consisting of H claim 1 , hydroxyl claim 1 , and halogen.5. A compound according to claim 1 , wherein at least one of Rand/or Ris Br or Cl6. A compound according to claim 1 , wherein Z is O.7. A compound according to claim 1 , wherein W is O.8. A compound according to claim 1 , wherein X is Br or Cl.9. A compound according to claim 1 , wherein n is 2 to 10.10. A compound according to claim 1 , wherein n is 4-8.11. A compound according to claim 1 , wherein Rand/or Ris Calkyl.12. A compound according to claim 1 , wherein m is 1 to 2.14. A polymer comprising a compound according to .15. A polymer according to claim 14 , wherein the compound is present in about 10% to about 50% by weight.16. A polymer according to claim 14 , wherein the compound is present in an amount sufficient to provide a phosphorus loading of about 0.01% to about 5%.17. A polymer according to claim 14 , wherein the compound is present in an amount sufficient to provide a phosphorus loading of about 1% to about 3%.18. A method of increasing the thermal stability of a polymer comprising adding the compound according to to the polymer.19. A method of increasing the maximum thermal decomposition temperature of a polymer comprising adding a compound according to to the polymer to form a modified polymer.20. A method according to claim 19 , wherein the thermal decomposition temperature of the modified polymer is above about 300° C. The present application claims priority to U.S. Application Ser. No. 62/035,041, filed Aug. 8, 2014, which is incorporated herein by reference.The patent or application ...

PHOSPHOROAMIDATE ESTERS, AND USE AND SYNTHESIS THEREOF

Phosphoramidate esters and related nucleotide analogs useful in polynucleotide sequencing techniques, and synthetic methods for preparing those compounds, are disclosed. These compounds include nucleotide phosphoramidates analogs that are modified on the alpha-phosphate to enable attachment of a variety of application-specific substituents such as tether molecules. 2. The compound of wherein each of Rand Ris selected from an alkyl group and an oxyalkyl group claim 1 , either of which terminates in a functional group selected from carbon-carbon double bond claim 1 , carbon-carbon triple bond claim 1 , hydroxyl claim 1 , amine claim 1 , azide claim 1 , hydrazine claim 1 , thiol claim 1 , carboxyl claim 1 , formyl claim 1 , hydroxylamino and halogen.3. The compound of wherein each of Rand Ris selected from an alkyl group and an oxyalkyl group claim 1 , either of which terminates in a linker group (LG1) claim 1 , the LG1 bonded to a tether (T).4. The compound of wherein LG1 and LG2 are triazole groups.5. The compound of wherein Ris —(CH)—C≡CH and q is an integer selected from 2-10.9. The compound of wherein Ris —C≡C—(CH)—C≡CH.13. The compound of wherein each of LG1 and LG2 is a triazole group.18. The process of further comprising reacting the N-phosphoroamidate-monoester triphosphate (160) with a tether precursor of the formula X-T-X where X represents a reactive functional group that is reactive with the terminating functional group of Rand R claim 17 , so as to form linker groups LG1 and LG2.19. The process of wherein X is an azide group and the terminating functional groups of Rand Rare alkyne groups. The present invention is in the field of phosphoroamidate ester compounds, synthetic methods for making said compounds, and methods for the determination of nucleic acids using said compounds, e.g., in the field of single molecule sequencing.Chemically modified nucleotides have been extensively used in the study of many complicated biological systems. In particular, ...

Prodrug compounds and their uses

Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver. Novel prodrug compounds of acid/alcohol derivatives such as phosphates, phosphonates, phosphonamidates, phosphoramidates, carboxylates, phenolates, and alkoxylates, their preparation and their uses are described. Some of the novel prodrug compounds described herein do not generate a vinyl keto reactive intermediate in the activation process. Another aspect includes the use of prodrugs to treat diseases that benefit from enhanced drug distribution to the liver and like tissues and cells.

Hydroformylation method having improved catalyst stability in reaction

Disclosed is a hydroformylation method having improved catalyst stability in a reaction. Advantageously, provided is a hydroformylation method in which a specific α,β-unsaturated carbonyl compound is incorporated during a hydroformylation reaction to prevent alkyl phosphite decomposed from a phosphite ligand from acting as a catalyst poison, thereby improving a yield of reaction and inhibiting decomposition of ligand and catalyst.

Method for reducing the chlorine content of organobisphosphites

The invention relates to a universally usable process for reducing the chlorine content of organobisphosphites.

PURIFICATION PROCESS

A process for reducing the level of contaminant metals in ligands used in the preparation of catalysts is disclosed. 1. A process comprising:(A) contacting a trivalent phosphorous ligand, a contaminant metal, a first solvent, a polar complexing agent and a second solvent to form a mixture,(B) obtaining a first phase comprising the ligand and the first solvent, and(C) obtaining a second phase comprising the second solvent and at least one complex of the contaminant metal and the polar complexing agent, and(D) separating the two phases.2. The process of wherein the two phases are predominantly in the liquid phase.3. The process of wherein the second solvent comprises water.4. The process of wherein the contaminant metal comprises iron.5. The process of wherein the polar complexing agent comprises ethylenediamine tetraacetic acid and alkali metal salts thereof.6. The process of conducted under conditions such that the concentration of metal salt in the presence of the ligand prior to step (A) is higher than the concentration of metal salt in first phase after step (D).7. The process of wherein the trivalent phosphorous ligand comprises at least one bisphosphite.8. The process of wherein the trivalent phosphorous ligand comprises at least one aryl or alkyl phosphine. This application claims priority from provisional application Ser. No. 61/541,291, filed Sep. 30, 2011, which is incorporated herein by reference in its entirety.The invention relates to the purification of ligands that can be used for the preparation of catalysts.Metal complex catalysts are a common class of catalysts and are used, for example, in commercial scale hydroformylation, hydrocyanation, olefin isomerization, cyclopropanation, and hydrogenation reactions. The presence of certain metals (primarily transition metals, e.g., iron) in hydroformylation systems is detrimental in that these contaminant metals can promote heavies formation or other side reactions.The source of contaminant metals, such as ...

DIPHOSPHITES HAVING AN OPEN, 2,4-METHYLATED OUTER UNIT

Diphosphites having an open, 2,4-methylated outer unit and use thereof in hydroformylation. 2. Compound according to claim 1 ,{'sup': 1', '3, 'sub': 1', '12, 'where R, Rare selected from: —H, —(C-C)-alkyl.'}3. Compound according to claim 1 ,{'sup': 1', '3, 'sub': 1', '12, 'where R, Rare —(C-C)-alkyl.'}4. Compound according to claim 1 ,{'sup': 1', '3, 'where R, Rare the same radical.'}5. Compound according to claim 1 ,{'sup': 2', '4, 'sub': 1', '12, 'where R, Rare selected from: —H, —O—(C-C) alkyl.'}6. Compound according to claim 1 ,{'sup': 2', '4, 'sub': 1', '12, 'wherein R, Rare —O—(C-C)-alkyl.'}7. Compound according to claim 1 ,{'sup': 2', '4, 'where R, Rare the same radical.'}8. Compound according to claim 1 ,{'sup': 1', '2', '3', '4, 'sub': '3', 'where R, R, R, Rare not all simultaneously —CH.'}10. Use of a compound according to in a ligand-metal complex for catalysis of a hydroformylation reaction.11. Process comprising the process steps of:a) initially charging an olefin,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'b) adding a compound according to and a substance containing a metal selected from: Rh, Ru, Co, Ir,'}{'sub': '2', 'c) supplying Hand CO,'}d) heating the reaction mixture from steps a) to c), with conversion of the olefin to an aldehyde. The invention relates to diphosphites having an open, 2,4-methylated outer unit and use thereof in hydroformylation.Phosphorus-containing compounds play a crucial role as ligands in a multitude of reactions, e.g. in hydrogenation, in hydrocyanation and also in hydroformylation.The reactions between olefin compounds, carbon monoxide and hydrogen in the presence of a catalyst to give the aldehydes with one carbon atom more are known as hydroformylation or the oxo process. In these reactions, compounds of the transition metals of group VIII of the Periodic Table of the Elements are frequently employed as catalysts. Known ligands are, for example, compounds from the phosphine, phosphite and phosphorite classes, ...

Novel phosphorus compounds, synthesis method thereof, and polycarbonate resin composition including them

The present disclosure relates to a phosphorus compound represented by the following Chemical Formula 1. In the above Chemical Formula 1, Ar is aryl and R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently H, substitutable linear or branched C 1 -C 20 alkyl and substitutable C 6 -C 20 aryl, the aryl includes a member selected from the group consisting of phenyl, biphenyl, naphthalene, fluorene, anthracene, phenanthrene, pyrene, fluoranthen, chrysene, benzofluoranthen, perylene, quinoline, indenoanthracene, indenophenanthrene, hydroanthracene, dibenzothiophen, dibenzofuran, and combinations thereof, and the substitution is substitution with C 1 -C 6 alkyl or C 6 -C 20 aryl, but may not be limited thereto.

PROCESS FOR REDUCING THE CHLORINE CONTENT OF ORGANOTETRAPHOSPHITES

Universally usable process for reducing the chlorine content of organotetraphosphites. 2. Process according to claim 1 ,wherein the solution with which the organotetraphosphite is contacted in step a) contains, as well as the at least one solvent and the at least one base, also max. 5% water based on the solvent content.3. Process according to claim 1 ,wherein the at least one base is selected from triethylamine and dimethylaminobutane.4. Process according to claim 1 ,wherein the organotetraphosphite used in process step a) has a chlorine content of 1500 ppm to 100 000 ppm.5. Process according to claim 1 ,wherein the purified organotetraphosphite has a chlorine content of <1000 ppm.6. Process according to claim 2 ,wherein the at least one base is selected from triethylamine and dimethylaminobutane.7. Process according to claim 2 ,wherein the organotetraphosphite used in process step a) has a chlorine content of 1500 ppm to 100 000 ppm.8. Process according to claim 3 ,wherein the organotetraphosphite used in process step a) has a chlorine content of 1500 ppm to 100 000 ppm.9. Process according to claim 2 ,wherein the purified organotetraphosphite has a chlorine content of <1000 ppm.10. Process according to claim 3 ,wherein the purified organotetraphosphite has a chlorine content of <1000 ppm.11. Process according to claim 4 ,wherein the purified organotetraphosphite has a chlorine content of <1000 ppm. The invention relates to a universally usable process for reducing the chlorine content of organotetraphosphites.Organophosphorus compounds have gained considerable industrial significance because of their wide range of use. They are used directly as plasticizers, flame retardants, UV stabilizers or as antioxidants. In addition, they are important intermediates in the production of fungicides, herbicides, insecticides and pharmaceuticals.A specific field of use of the organophosphorus compounds is catalysis:For instance, especially phosphines, phosphites and ...

CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS

The present invention is directed to polyphosphorylated and pyrophosphate derivatives of cyclitols. More particularly, the invention relates to polyphosphorylated and pyrophosphate derivatives of inositols. The invention also relates to compositions of the polyphosphorylated and pyrophosphate derivatives of inositol and other similar, more lipophilic derivatives, and their use as allosteric effectors, cell-signaling molecule analogs, and therapeutic agents. 131.-. (canceled)32. A composition comprising a pyrophosphate inositol which reduces hemoglobin's oxygen affinity , wherein:the pyrophosphate is an internal pyrophosphate;the inositol is cis-inositol, epi-inositol, allo-inositol, muco-inositol, neo-inositol, scyllo-inositol, (+) chiro-inositol, or (−) chiro-inositol, and wherein the pyrophosphate inositol is monopyrophosphate, bispyrophosphate, or trispyrophosphate; andthe pyrophosphate inositol comprises a derivatized hydroxyl selected from alkoxy (—OR) or acyloxy (—OCOR),where R is selected from alkyl, aryl, acyl, aralkyl, alkenyl, alkynyl, heterocyclyl, polycyclyl, carbocycle, amino, acylamino, amido, alkylthio, sulfonate, alkoxyl, or sulfoxido, or a salt thereof.33. The composition of claim 32 , wherein the pyrophosphate inositol is complexed with a cation to form a salt claim 32 , and wherein the cation is an alkali metal cation claim 32 , an alkaline metal cation claim 32 , an ammonium claim 32 , or an organic cation.34. The composition of claim 32 , wherein R is a lower alkyl.35. The composition of claim 34 , where R is methyl.36. The composition of claim 32 , wherein the inositol is scyllo-inositol.37. The composition of claim 32 , wherein the inositol is monopyrophosphate.38. The composition of claim 32 , wherein the inositol is bispyrophosphate.39. A pharmaceutical composition claim 32 , comprising a pyrophosphate inositol wherein:the pyrophosphate is an internal pyrophosphate;the inositol is cis-inositol, epi-inositol, allo-inositol, muco-inositol, neo ...

Electrolyte Solution for Lithium Secondary Battery and Lithium Secondary Battery Including the Same

An electrolyte solution for a lithium secondary battery includes an organic solvent, a lithium salt, and a pentaerythritol diphosphite-based compound including at least one substituent selected from the group consisting of a silyl group, a sulfonyl group, a phosphoryl group and a phosphino group. A lithium secondary including the electrolyte solution is provided.

PROCESSES FOR PURIFYING LIGANDS

Embodiments of the present invention are directed to processes for purifying ligands such as organopolyphosphite ligands. In one embodiment, a process comprises: (a) receiving a solid organopolyphosphite compound that has been recrystallized or triturated at least once, wherein the solid organopolyphosphite compound comprises greater than one weight percent of an oxidized phosphite impurity and wherein the organopolyphosphite compound is substantially free of solvent; (b) slurrying the solid organopolyphosphite compound in a Cor higher alcohol at a temperature of at least 60° C. for at least 20 minutes to reduce the oxidized phosphite impurity in the solid phase; and (c) removing liquid comprising dissolved oxidized phosphite impurity from the slurry, wherein the residual oxidized phosphite impurity content of the organopolyphosphite compound following step (c) is 1 weight percent or less. 1. A process comprising:(a) receiving a solid organopolyphosphite compound that has been recrystallized or triturated at least once, wherein the solid organopolyphosphite compound comprises greater than one weight percent of an oxidized phosphite impurity and wherein the organopolyphosphite compound is substantially free of solvent;{'sub': '2', '(b) slurrying the solid organopolyphosphite compound in a Cor higher alcohol at a temperature of at least 60° C. for at least 20 minutes to reduce the oxidized phosphite impurity in the solid phase; and'}(c) removing liquid comprising dissolved oxidized phosphite impurity from the slurry, wherein the residual oxidized phosphite impurity content of the organopolyphosphite compound following step (c) is 1 weight percent or less.2. The process of claim 1 , wherein the organopolyphosphite is an organobisphosphite.3. The process of claim 1 , wherein the dissolved oxidized phosphite impurity is removed by filtration.4. The process of claim 1 , wherein the dissolved oxidized phosphite impurity is removed by centrifugation.5. The process of claim ...

BISPHOSPHONATE COMPOUNDS

Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism. 167.-. (canceled) This application claims the benefit of priority from U.S. Provisional Patent Application No. 61/254,886, which was filed on Oct. 26, 2009, the contents of which are incorporated herein in their entirety.Novel bisphosphonate cyclic acetal compounds are disclosed, as well as their uses as antiresorptive agents and for the treatment and prevention of disorders associated with bone metabolism, such as abnormal calcium and phosphate metabolism. Processes for preparing the novel bisphosphonate cyclic acetal compounds, as well as methods of using them and pharmaceutical compositions containing them are also disclosed.Bisphosphonates were first developed to complex calcium in hard water to improve detergent performance. Bisphosphonates have since been found to be useful in the treatment and prevention of diseases or conditions characterized by abnormal calcium and phosphate metabolism. Such conditions may be divided into two broad categories:1. Conditions which are characterized by anomalous mobilization of calcium and phosphate leading to general or specific bone loss or excessively high calcium and phosphate levels in the fluids of the body. Such conditions are sometimes referred to as pathological hard tissue demineralization.2. Conditions which cause or result from deposition of calcium and phosphate anomalously in the body. These conditions are sometimes referred to as pathological calcifications.The first category includes osteoporosis, a condition in which bone hard tissue is lost disproportionately to the development of new hard tissue ultimately resulting in fractures. Essential quantities of cancellous bone are lost, and marrow and bone spaces become ...

COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING

The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS. 12-. (canceled)56-. (canceled)9. The pharmaceutical composition of claim 3 , wherein each Xis —N—.10. The pharmaceutical composition of claim 3 , wherein each Xis —N—.11. (canceled)12. The pharmaceutical composition of claim 3 , wherein Xis —O—.13. The pharmaceutical composition of claim 3 , wherein Xis —O—.14. (canceled)15. The pharmaceutical composition of claim 3 , wherein Xand Xare both oxygen.16. The pharmaceutical composition of claim 3 , wherein Xand Xare both sulfur.17. The pharmaceutical composition of claim 3 , wherein Rand Rare independently selected from the group consisting of hydrogen claim 3 , halogen claim 3 , —NH— claim 3 , and —OR claim 3 , wherein Ris hydrogen or Calkyl.18. The pharmaceutical composition of claim 17 , wherein at least one of Rand Ris —OH.19. The pharmaceutical composition of claim 3 , wherein each Rand Ris independently selected from the group consisting of hydrogen claim 3 , halogen claim 3 , —NH— claim 3 , and —OR claim 3 , wherein Ris hydrogen or Calkyl; and each Rand Ris hydrogen.20. The pharmaceutical composition of claim 3 , wherein each of R claim 3 , R claim 3 , R claim 3 , R claim 3 , and Ris independently selected from the group consisting of hydrogen claim 3 , halogen claim 3 , —OH claim 3 , —SH claim 3 , —NH claim 3 , and —C(O)NH.21. The pharmaceutical composition of claim 20 , wherein each Rand Rare independently selected from the group consisting of hydrogen claim 20 , halogen claim 20 , —NH claim 20 , and —OR claim 20 , wherein Ris hydrogen or Calkyl.22. The pharmaceutical composition of claim 3 , wherein each R claim 3 , R claim 3 , and Ris independently selected from the group consisting of hydrogen and halogen.23. The pharmaceutical composition of claim 22 , wherein each of R claim 22 , R claim 22 , and Ris hydrogen.24. The pharmaceutical ...

PROCESS FOR THE PREPARATION OF DOPO-DERIVED COMPOUNDS AND COMPOSITIONS THEREOF

This invention relates to a process for producing compounds derived from 9,10-Dihydro-9-Oxa-10-Phosphaphenantrene-10-oxide (DOPO). In particular, the invention relates to producing DOPO-derived compounds by reacting DOPO with diol compounds in the presence of a catalyst. This invention also relates to DOPO derived composition containing a high melting point diastereomer. The DOPO derived compounds may be useful as flame-retardants. 2. The process of claim 1 , wherein n is 2 to 6 and R claim 1 , R claim 1 , Rand Rare hydrogen.4. The process of claim 1 , wherein both the solvent and the entrainer are present.5. The process of claim 1 , wherein said catalyst is an alky halide claim 1 , alkali halides claim 1 , alkaline earth metal halides claim 1 , transition metals and their halides or acid catalysts.6. The process of claim 1 , wherein the temperature of the reaction ranges from about 100° C. to about 250° C.7. The process of claim 1 , wherein the a product of the reaction is water and wherein the water and the diol compound of Formula B or ethylene glycol are continuously recycled back to reactor.8. The process of claim 1 , wherein the catalyst is an acid catalyst.12. The composition of claim 11 , wherein said acid catalyst is sulfuric acid claim 11 , aryl sulfonic acid claim 11 , alkyl sulfonic acid claim 11 , aralkyl sulfonic acid claim 11 , hydrochloric acid claim 11 , hydrobromic acid claim 11 , hydrofluoric acid claim 11 , oxalic acid claim 11 , perchloric acid claim 11 , trifluoromethane sulfonic acid claim 11 , fluorosulfonic acid claim 11 , nitric acid claim 11 , phosphoric acid claim 11 , phosphonic acids claim 11 , phosphinic acids aluminum chloride claim 11 , diethyl aluminum chloride claim 11 , triethylaluminum/hydrogen chloride claim 11 , ferric chloride claim 11 , zinc chloride claim 11 , antimony trichloride claim 11 , stannic chloride claim 11 , boron trifluoride claim 11 , acidic zeolites claim 11 , acidic clays claim 11 , polymeric sulfonic acids ...

COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING

The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS. 178-. (canceled)83. The compound of claim 79 , wherein each Xand Xis —N—.84. The compound of claim 79 , wherein Xand Xare —O—.85. The compound of claim 79 , wherein Xand Xare both sulfur.86. The compound of claim 79 , wherein Ris selected from the group consisting of hydrogen claim 79 , halogen claim 79 , and —OH.87. The compound of claim 79 , wherein Ris selected from the group consisting of hydrogen claim 79 , halogen claim 79 , and —OH.88. The compound of claim 79 , where each of R claim 79 , R claim 79 , and Ris hydrogen.89. The compound of claim 79 , wherein Rand Rare each —NH.90. The compound of claim 79 , wherein Rand Rare each hydrogen.93. The compound of claim 92 , wherein Xand Xare both sulfur.94. The compound of claim 92 , wherein Ris selected from the group consisting of hydrogen claim 92 , halogen claim 92 , and —OH.95. The compound of claim 92 , wherein Ris selected from the group consisting of hydrogen claim 92 , halogen claim 92 , and —OH.96. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.97. A method for treatment or prevention of cancer claim 96 , comprising administering to a subject in need thereof the pharmaceutical composition of . The present application is a divisional of U.S. application Ser. No. 14/787,611, filed on Oct. 28, 2015, now U.S. Pat. No. 9,840,533, which is a U.S. National Phase application under 35 U.S.C. § 371 of International Patent Application No. PCT/US2014/035909, filed on Apr. 29, 2014, which claims priority to U.S. provisional patent application No. 61/817,269, filed Apr. 29, 2013, and 61/819,369, filed May 3, 2013, the entire contents of each of which are hereby incorporated by reference herein.The specification includes a Sequence Listing in the form of an ...

PHOSPHOROAMIDATE ESTERS, AND USE AND SYNTHESIS THEREOF

Phosphoramidate esters and related nucleotide analogs useful in polynucleotide sequencing techniques, and synthetic methods for preparing those compounds, are disclosed. These compounds include nucleotide phosphoramidates analogs that are modified on the alpha-phosphate to enable attachment of a variety of application-specific substituents such as tether molecules. 2. The compound of wherein each of Rand Ris selected from an alkyl group and an oxyalkyl group claim 1 , either of which terminates in a functional group selected from carbon-carbon double bond claim 1 , carbon-carbon triple bond claim 1 , hydroxyl claim 1 , amine claim 1 , azide claim 1 , hydrazine claim 1 , thiol claim 1 , carboxyl claim 1 , formyl claim 1 , hydroxylamino and halogen.3. The compound of wherein each of Rand Ris selected from an alkyl group and an oxyalkyl group claim 1 , either of which terminates in a linker group (LG1) claim 1 , the LG1 bonded to a tether (T).4. The compound of wherein LG1 and LG2 are triazole groups.5. The compound of wherein Ris —(CH)—C≡CH and q is an integer selected from 2-10.9. The compound of wherein Ris —C≡C—(CH)—C≡CH.13. The compound of wherein each of LG1 and LG2 is a triazole group.18. The process of further comprising reacting the N-phosphoroamidate-monoester triphosphate (160) with a tether precursor of the formula X-T-X where X represents a reactive functional group that is reactive with the terminating functional group of Rand R claim 17 , so as to form linker groups LG1 and LG2.19. The process of wherein X is an azide group and the terminating functional groups of Rand Rare alkyne groups. The present invention is in the field of phosphoroamidate ester compounds, synthetic methods for making said compounds, and methods for the determination of nucleic acids using said compounds, e.g., in the field of single molecule sequencing.Chemically modified nucleotides have been extensively used in the study of many complicated biological systems. In particular, ...

CRYSTALLINE LIGAND

A ligand crystal structure of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bisdibenzo[d,f][1,3,2]-dioxaphosphepin. Formule (I) 1. A crystalline form of 6 ,6′-[[3 ,3′ ,5 ,5′-tetrakis(1 ,1-dimethylethyl)-[1 ,1′-biphenyl]-2 ,2′-diyl]bis(oxy)]bisdibenzo[d ,f][1 ,3 ,2]-dioxaphosphepin , which displays its two strongest reflections , stated as 2Θ values , at 7.8±0.2° and 19.7±0.2° in an X-ray powder diffractogram , measured at 25° C. with Cu-Kα radiation.3. The crystalline form of that is solvent-free.4. The crystalline form of lacking a significant reflection at 8.5±0.2° 2θ in an X-ray powder diffractogram claim 1 , measured at 25° C. with Cu-Kα radiation.5. The crystalline form of having a melting point of 202-208° C. claim 1 , as determined by DSC.6. The crystalline form of having a DSC plot that exhibits an initial endothermic transition with a peak at 206° C.7. The crystalline form of having the XRD diffractogram of .8. The crystalline form of having the TGA plot of line B. The invention relates to a crystalline form of a bisphosphite ligand.Bisphosphites are commonly used as ligands for transition-metal catalyzed reactions such as hydroformylation and hydrocyanation. One commonly used bisphosphite ligand is 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bisdibenzo[d,f][1,3,2]-dioxaphosphepin, (hereinafter Ligand A), shown in Formula 1:Like many organic molecules, Ligand A is a crystalline material capable of existing in a number of forms. A crystalline non-solvate and various solvate forms are disclosed in U.S. Pat. No. 8,796,481 and Yuan Hao, et al. “Crystal Structure of 6,6′-(3,3′5,5′-tetra-tertbutylbiphenyl-2,2′-diyl)Bis(oxy)didibenzo[d,f]-[1,3,2]dioxaphosphepine” ., Vol 31, 673 (2012).US 2014/0288322 A1 discloses a process for preparing a fast drying form of Ligand A via treatment with a secondary alcohol, e.g., isopropanol, at 72-75° C. for several hours. The crystal structure of the resulting ...

BISPHOSPHITES HAVING AN UNSYMMETRIC OUTER BIPHENOL UNIT

Bisphosphites having at least one unsymmetric outer biphenol unit are useful for the hydroformylation of an olefin. 2. The compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R, R, R, R, R, R, R, Rare each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, —(C-C)-alkyl, —O—(C-C)-alkyl, —O—(C-C)-aryl, —S-alkyl, and —S-aryl.'}3. The compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R, R, R, R, R, R, R, Rare each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, —(C-C)-alkyl, —O—(C-C)-alkyl, and —O—(C-C)-aryl.'}4. The compound according to claim 1 ,{'sup': 1', '2', '3″', '4', '5', '6', '7', '8, 'wherein R″, R″, R, R″, R″, R″, R″, R″ are each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, —(C-C)-alkyl, —O—(C-C)-alkyl, and —O—(C-C)-aryl.'}5. The compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R, R, R, R, R, R, R, Rare each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, —(C-C)-alkyl, —O—(C-C)-alkyl, and —O—(C-C)-aryl.'}6. The compound according to claims 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R′, R′, R′, R′, R′, R′, R′, R′ are each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, —(C-C)-alkyl, —O—(C-C)-alkyl, and —O—(C-C)-aryl.'}7. The compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R″, R″, R″, R″, R″, R″, R″, R″ are each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, —(C-C)-alkyl, —O—(C-C)-alkyl, and —O—(C-C)-aryl.'}8. The compound according to claim 1 ,{'sup': 1', '1′', '1, 'wherein R, R and R′ are the same radical; and'}{'sup': 8', '8', '8″, 'R, R′ and Rare the same radical.'}9. The compound according to claim 1 ,{'sup': 1', '8, ' ...

BISPHOSPHITE LIGANDS BASED ON BENZOPINACOL

Bisphosphite ligands based on benzopinacol, and the use thereof in hydroformylation. 2. Compound according to claim 1 ,{'sup': 5', '8, 'sub': 1', '12, 'wherein Rand Rare —(C-C)-alkyl.'}3. Compound according to claim 1 ,{'sup': 5', '8', 'tert, 'wherein Rand Rare -Bu.'}4. Compound according to claim 1 ,{'sup': 6', '7, 'sub': 1', '2', '1', '12, 'wherein R, Rare selected from: —(C-C)-alkyl, —O—(C-C)-alkyl.'}5. Compound according to claim 1 ,{'sup': 6', '7', 'tert, 'sub': '3', 'wherein Rand Rare —OCHor -Bu.'}6. Compound according to claim 1 ,{'sup': 1', '2', '3', '4, 'sub': 1', '12, 'wherein R, R, R, Rare selected from —H, —(C-C)-alkyl.'}7. Compound according to claim 1 ,{'sup': 1', '2', '3', '4', 'tert, 'wherein R, R, R, Rare —H or -Bu.'}9. Process comprising the process steps of:a) initially charging an ethylenically unsaturated compound:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'b) adding a compound according to and a substance comprising Rh;'}{'sub': '2', 'c) feeding in Hand CO,'}d) heating the reaction mixture from a) to c), with conversion of the olefin to an aldehyde.10. Process according to claim 9 ,wherein the ethylenically unsaturated compound in process step a) is selected from: ethene, propene, 1-butene, cis- and/or trans-2-butene, isobutene, 1,3-butadiene, 1-pentene, cis- and/or trans-2-pentene, 2-methyl-1-butene, 3-methyl-1-butene, 2-methyl-2-butene, hexene, tetramethylethylene, heptene, 1-octene, 2-octene, di-n-butene, or mixtures thereof.11. Process according to claim 9 ,{'sub': 2', '4', '12, 'wherein the substance comprising Rh is selected from: Rh(acac)(CO), [(acac)Rh(COD)](Umicore, acac=acetylacetonate anion; COD=1,5-cyclooctadiene), RhCO.'}12. Process according to claim 9 ,wherein CO is fed in in process step c) at a pressure in the range from 1 to 6 MPa (10 to 60 bar).13. Process according to claim 9 ,wherein the reaction mixture is heated in process step d) to a temperature in the range from 80° C. to 160° C. The present invention relates to ...

LIGANDS BASED ON PHOSPHONITE PHOSPHITES

Ligands based on phosphonite phosphites, and the use thereof in hydroformylation. 2. Compound according to claim 1 ,{'sup': 5', '8, 'sub': 1', '12, 'wherein Rand Rare —(C-C)-alkyl.'}3. Compound according to claim 1 ,{'sup': 5', '8', 'tert, 'wherein Rand Rare -Bu.'}4. Compound according to claim 1 ,{'sup': 6', '7, 'sub': 1', '12', '1', '12, 'wherein R, Rare selected from: —(C-C)-alkyl, —O—(C-C)-alkyl.'}5. Compound according to claim 1 ,{'sup': 6', '7', 'tert, 'sub': '3', 'wherein Rand Rare —OCHor -Bu.'}6. Compound according to claim 1 ,{'sup': 1', '2', '3', '4, 'sub': 1', '12, 'wherein R, R, R, Rare selected from —H, —(C-C)-alkyl.'}7. Compound according to claim 1 ,{'sup': 1', '2', '3', '4', 'tert, 'wherein R, R, R, Rare —H or -Bu.'}9. Process comprising the process steps of:a) initially charging an ethylenically unsaturated compound;{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'b) adding a compound according to and a substance comprising Rh;'}{'sub': '2', 'c) feeding in Hand CO,'}d) heating the reaction mixture from a) to c), with conversion of the olefin to an aldehyde.10. Process according to claim 9 ,wherein the ethylenically unsaturated compound in process step a) is selected from: ethene, propene, 1-butene, cis- and/or trans-2-butene, isobutene, 1,3-butadiene, 1-pentene, cis- and/or trans-2-pentene, 2-methyl-1-butene, 3-methyl-1-butene, 2-methyl-2-butene, hexene, tetramethylethylene, heptene, 1-octene, 2-octene, di-n-butene, or mixtures thereof.11. Process according to claim 9 ,{'sub': 2', '4', '12, 'wherein the substance comprising Rh is selected from: Rh(acac)(CO), [(acac)Rh(COD)] (Umicore, acac=acetylacetonate anion; COD=1,5-cyclooctadiene), RhCO.'}12. Process according to claim 9 ,wherein CO is fed in in process step c) at a pressure in the range from 1 to 6 MPa (10 to 60 bar).13. Process according to claim 9 ,wherein the reaction mixture is heated in process step d) to a temperature in the range from 80° C. to 160° C. The present invention relates to ...

Novel Compounds

A compound of Formula (I) 127.-. (canceled)29. A compound of claim 28 , or a pharmaceutically acceptable salt thereof claim 28 , wherein:{'sup': '35', 'Ris selected from: F and OH; and'}{'sup': '36', 'Ris selected from: F and OH;'}{'sup': 35', '36, 'provided: at least one of Rand Ris F.'}30. A compound of claim 28 , or a pharmaceutically acceptable salt thereof claim 28 , wherein:{'sup': '35', 'Ris OH; and'}{'sup': '36', 'Ris F.'}32. A pharmaceutical composition comprising a compound of claim 28 , or a pharmaceutically acceptable salt thereof claim 28 , and one or more of pharmaceutically acceptable excipients.33. A method of treating a disease state selected from: inflammation claim 28 , allergic diseases claim 28 , autoimmune diseases claim 28 , human immunodeficiency virus (HIV) claim 28 , infectious diseases claim 28 , cancer claim 28 , and pre-cancerous syndromes claim 28 , in a mammal in need thereof claim 28 , which comprises administering to such mammal a therapeutically effective amount of a compound of Formula IV claim 28 , or a pharmaceutically acceptable salt thereof claim 28 , as described in .34. The method of wherein the mammal is a human.35. A composition comprising a compound of claim 28 , or a pharmaceutically acceptable salt thereof claim 28 , and an antigen or antigen composition.36. A vaccine composition comprising an antigen or antigen composition and a compound of claim 28 , or a pharmaceutically acceptable salt thereof.37. An immugenic composition comprising an antigen or antigen composition and a compound of claim 28 , or a pharmaceutically acceptable salt thereof.38. A composition comprising a compound of claim 28 , or a pharmaceutically acceptable salt thereof claim 28 , and one or more immunostimulatory agents.39. A method of treating a disease selected from: HBV claim 28 , HCV claim 28 , influenza claim 28 , skin warts claim 28 , multiple sclerosis claim 28 , and allergic inflammation claim 28 , in a human in need thereof claim 28 , ...

BISPHOSPHITE LIGANDS BASED ON BENZOPINACOL AND 1,3-PROPANEDIOL

Bisphosphite ligands based on benzopinacol and 1,3-propanediol, and the use thereof in hydroformylation. 2. Compound according to claim 1 ,{'sup': 7', '10, 'sub': 1', '12, 'wherein Rand Rare —(C-C)-alkyl.'}3. Compound according to claim 1 ,{'sup': 7', '10', 'tert, 'wherein Rand Rare -Bu.'}4. Compound according to claim 1 ,{'sup': 8', '9, 'sub': 1', '12', '1', '12, 'wherein R, Rare selected from: —(C-C)-alkyl, —O—(C-C)-alkyl.'}5. Compound according to claim 1 ,{'sup': 8', '9', 'tert, 'sub': '3', 'wherein Rand Rare —OCHor -Bu.'}6. Compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6, 'sub': 1', '12', '6', '12, 'wherein R, R, R, R, R, Rare selected from —H, —(C-C)-alkyl, —(C-C)-aryl.'}7. Compound according to claim 1 ,{'sup': 1', '2', '5', '6, 'wherein R, R, R, Rare —H.'}9. Process comprising the process steps of:a) initially charging an ethylenically unsaturated compound;{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'b) adding a compound according to and a substance comprising Rh;'}{'sub': '2', 'c) feeding in Hand CO,'}d) heating the reaction mixture from a) to c), with conversion of the olefin to an aldehyde.10. Process according to claim 9 ,wherein the ethylenically unsaturated compound in process step a) is selected from: ethene, propene, 1-butene, cis- and/or trans-2-butene, isobutene, 1,3-butadiene, 1-pentene, cis- and/or trans-2-pentene, 2-methyl-1-butene, 3-methyl-1-butene, 2-methyl-2-butene, hexene, tetramethylethylene, heptene, 1-octene, 2-octene, di-n-butene, or mixtures thereof.11. Process according to claim 9 ,{'sub': 2', '4', '12, 'wherein the substance comprising Rh is selected from: Rh(acac)(CO), [(acac)Rh(COD)](Umicore, acac=acetylacetonate anion; COD=1,5-cyclooctadiene), RhCO.'}12. Process according to claim 9 ,wherein CO is fed in in process step c) at a pressure in the range from 1 to 6 MPa (10 to 60 bar).13. Process according to claim 9 ,wherein the reaction mixture is heated in process step d) to a temperature in the range from 80 ...

CYCLIC DI-NUCLEOTIDES AS MODULATORS OF STING

A compound of formula (1) 2. A compound or pharmaceutically acceptable salt thereof according to wherein at least one of Yand Yis CH3. A compound or pharmaceutically acceptable salt thereof according to wherein Yis CH and Yis O.4. A compound or pharmaceutically acceptable salt thereof according to wherein Yis O and Yis CH.5. A compound or pharmaceutically acceptable salt thereof according to wherein Yand Yare both CH.6. A compound or pharmaceutically acceptable salt thereof according to wherein Yand Yare both O and at least one of Rand Ris F.7. A compound or pharmaceutically acceptable salt thereof according to wherein Ris NHand Ris H.8. A compound or pharmaceutically acceptable salt thereof according to wherein Ris NHand Ris OH.9. A compound or pharmaceutically acceptable salt thereof according to wherein Ris NH claim 1 , Ris H claim 1 , Ris NHand Ris OH10. A compound or pharmaceutically acceptable salt thereof according to wherein Ris NH claim 1 , Ris H claim 1 , Ris NH claim 1 , Ris OH claim 1 , Ris OH and Ris OH11. A compound according to which is{'sup': 5', '5', '6,10, '(1S,6R,8R,9S,10R,15R,17R,18R)-17-(2-Amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-8-(6-amino-9H-purin-9-yl)-3,9,12,18-tetrahydroxy-2,4,11,13-tetraoxa-3λ,12λ-diphosphatricyclo[13 2 1 0]octadecane-3,12-dione,'}{'sup': 5', '5', '6,10, '(1R,6R,8R,9S,1R,15R,17R,18R)-17-(2-Amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-8-(6-amino-9H-purin-9-yl)-3,9,12,18-tetrahydroxy-2,4,11,13,16-pentaoxa-3λ,12λ-diphosphatricyclo[13 2 1 0]octadecane-3,12-dione,'}{'sup': 5', '5', '6,10, '(1S,6R,8R,9R,10S,15R,17R,18R)-17-(2-Amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-8-(6-amino-9H-purin-9-yl)-3,9,12,18-tetrahydroxy-2,4,7,11,13-pentaoxa-3λ,12λ-diphosphatricyclo[13 2 1 0]octadecane-3,12-dione,'}{'sup': 5', '5', '6,10, '(1S,6R,8R,9R,10R,15R,17R,18R)-17-(2-Amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-8-(6-amino-9H-purin-9-yl)-9-fluoro-3,12,18-trihydroxy-2,4,7,11,13-pentaoxa-3λ,12λ-diphosphatricyclo[13 2.1 0]octadecane-3,12-dione,'}or a ...

Preventing Solvent of Crystallization in Production of Polyphosphite Ligands

Residual wash solvent, e.g., ethyl acetate, is removed from polyphosphite, e.g., bisphosphite, crystals by a process comprising the steps of: A. Mixing the polyphosphite crystals and residual wash solvent with a secondary alcohol, e.g., isopropyl alcohol (IPA), to form a mixture of polyphosphite crystals, residual wash solvent and secondary alcohol, and B. Drying the mixture to remove the residual wash solvent and secondary alcohol to a content of less than 0.5 wt % based on the weight of the polyphosphite crystals. 1. A process for removing residual wash solvent from polyphosphite crystals , the process comprising the steps of:A. Mixing the polyphosphite crystals and residual wash solvent with a secondary alcohol to form a mixture of polyphosphite crystals, residual wash solvent and secondary alcohol, andB. Drying the mixture to remove the residual wash solvent and secondary alcohol to a content of less than 0.5 wt % based on the weight of the polyphosphite crystals.2. The process of comprising the further step of separating the polyphosphite crystals from the residual wash solvent and secondary alcohol before drying the crystals to a content of less than 0.5 wt % based on the weight of the polyphosphite crystals.3. The process of in which the crystals are separated from the residual wash solvent and secondary alcohol by centrifugation or filtration.4. The process of in which the residual wash solvent is an alkyl ester.5. The process of in which the alkyl ester is ethyl or propyl acetate.6. The process of in which the polyphosphite is a bisphosphite.7. The process of in which the secondary alcohol is a C-Csecondary alcohol.8. The process of in which the secondary alcohol is isopropyl alcohol.9. The process of in which the crystals are dried at a temperature of 20° C. to 100° C. and a pressure less than atmospheric (760 mmHg or 101.325 kPa).10. Polyphosphite crystals made by the process of . 1. Field of the InventionThis invention relates to polyphosphite ligands. ...

Stable long-term method for producing c5-aldehydes

The invention relates to a process for preparing aldehydes having five carbon atoms, in which an input mixture containing 10% by weight to 50% by weight of linear butenes and less than 5% by weight of 1-butene is hydroformylated with synthesis gas in the presence of a catalyst system comprising rhodium and at least one bisphosphite ligand, wherein the hydroformylation is effected in a reactor from which, over an operating period, a cycle gas containing at least a portion of the products and unconverted reactants from the hydroformylation is continuously drawn off and partly condensed, and uncondensed components of the cycle gas are recycled into the reactor, and wherein, after the operating period has expired, the hydroformylation is stopped, the reactor is freed of reaction residues and the hydroformylation is restarted. It is based on the problem of making such a process more economically viable. The problem is solved by using a bisphosphite of the formula (1) and/or (2) as ligand, extending the operating period to more than 8000 h, and not separating solid reaction residues out of the reactor during the course of the operating period.

Preparation of 6,6'-((3,3'-di-tert-butyl-5,5'-dimethoxy-[1,1'-biphenyl]-2,2'-diyl)bis(oxy))bis(2,4,8,10-tetramethyldibenzo[d,f][1,3,2]dioxaphosphepine)

A process for preparing 6,6′-((3,3′-di-tert-butyl-5,5′-dimethoxy-[1,1′-biphenyl]-2,2′-diyl)bis(oxy))bis(2,4,8,10-tetramethyldibenzo[d,f][1,3,2]dioxaphosphepine) is provided.

NOVEL ORGANOPHOSPHORUS COMPOUNDS BASED ON ANTHRACENETRIOL

The subject matter of the present invention is a plurality of products and the use thereof as a catalytically active composition in a method for producing aldehydes. 5. The compound according to claim 2 ,{'sup': III', '2', '3, 'wherein W is a P(G)(G) group.'}6. The compound according to claim 2 ,{'sup': 2', '3', '18, 'wherein G, and Gare —OR.'}7. The compound according to claim 4 ,{'sup': 5', '6', '41, 'wherein G, and Gare —OR.'}8. The compound according to claim 1 ,{'sup': 1', '2, 'wherein X, and Xare O.'}9. The compound according to claim 1 ,{'sup': '1', 'wherein Gcomprises a bisarylene group having any desired further substitution.'}11. The compound according to claim 1 ,{'sup': 2', '3, 'wherein Gand Gare linked to each other covalently.'}13. The compound according to claim 4 ,{'sup': 5', '6, 'wherein Gand Gare linked to each other covalently.'}15. The compound according to claim 4 ,{'sup': III', '2', '3', 'III', '5', '6, 'wherein the P(G)(G) group corresponds in terms of structural formula to the P(G)(G) group.'}16. A complex claim 4 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the compound according to , and'}a central metal atom,{'sup': 'III', 'wherein the compound is coordinated onto the central metal atom via at least one P.'}17. The complex according to claim 16 ,wherein the central metal atom is one of groups 8 to 10 metals.18. The complex according to claim 17 , wherein the central metal atom is rhodium.19. A composition claim 17 , comprising:a central metal atom, and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'at least two compounds according to ,'}whereina first compound is not coordinated onto a central metal atom, and{'sup': 'III', 'a second compound is coordinated onto the central metal atom via at least one P.'}2021-. (canceled)22. A multiphasic reaction mixture claim 17 , comprising:an olefinically unsaturated hydrocarbon mixture,a gas mixture comprising carbon monoxide and hydrogen,aldehydes, and{'claim-ref': {'@idref': ' ...

EXTRACTION SOLVENT CONTROL FOR REDUCING STABLE EMULSIONS

Disclosed herein are methods for recovering diphosphite-containing compounds from mixtures comprising organic mononitriles and organic dinitriles, using liquid-liquid extraction. Also disclosed are pre-treatments to enhance extractability of the diphosphite-containing compounds. 1. A process for recovering diphosphite-containing compounds from a feed mixture comprising diphosphite-containing compounds , organic mononitriles , organic dinitriles and a Lewis acid in a multistage countercurrent liquid-liquid extractor with extraction solvent comprising aliphatic hydrocarbon , cycloaliphatic hydrocarbon or a mixture of aliphatic and cycloaliphatic hydrocarbon , said process comprising:a) flowing the feed mixture to a mixing section of a mixer-settler in the first stage of the multistage countercurrent liquid-liquid extractor;b) contacting the feed mixture with extraction solvent from the second stage of the multistage countercurrent liquid-liquid extractor in the mixing section of the mixer-settler of the first stage to form a mixed phase comprising a light phase and a heavy phase, wherein the light phase comprises extraction solvent and extracted diphosphite-containing compounds, and wherein the heavy phase comprises organic mononitrile and organic dinitriles;c) passing the mixture from step (b) to a settling section in the mixer-settler of the first stage, wherein the mixed phase separates into the light phase and the heavy phase; and 'wherein a complex of Lewis acid and Lewis base is formed in the settling section in the mixer-settler of the first stage, wherein at least a portion of the light phase is withdrawn from the settling section and treated to recover diphosphite-containing compounds extracted into the light phase, and wherein at least a portion of the heavy phase is passed to the second stage of the multistage countercurrent liquid-liquid extractor.', 'd) introducing a Lewis base into the settling section of the first stage,'}2. The process of claim 1 , ...

3-PHENYL-BENZOFURAN-2-ONE DIPHOSPHITE DERIVATIVES AS STABILIZERS

The invention relates to a composition comprising an organic material susceptible to oxidative, thermal or light-induced degradation and a compound of formula I-P, I-O or I-M. Further embodiments are a compound of formula I-P, I-O or I-M, a process for protection of the organic material by the compound, the use of the compound against degradation of the organic material, an additive composition comprising the compound, a process for manufacturing the compound and an intermediate involved therein. 2: The composition according to claim 1 , wherein the organic material is a polymer claim 1 , an oligohydroxy compound claim 1 , a wax claim 1 , a fat or a mineral oil.3: The composition according to claim 2 , wherein the organic material is a polymer claim 2 , which is a polyolefin or a copolymer thereof claim 2 , a polystyrene or a copolymer thereof claim 2 , a polyurethane or a copolymer thereof claim 2 , a polyether claim 2 , which is obtained by the polymerization of an epoxide claim 2 , an oxetane or a tetrahydrofuran claim 2 , or a copolymer thereof claim 2 , a polyester or a copolymer thereof claim 2 , a polycarbonate or a copolymer thereof claim 2 , a poly(vinyl chloride) or a copolymer thereof claim 2 , a poly(vinylidene chloride) or a copolymer thereof claim 2 , a polysulfone or a copolymer thereof claim 2 , a poly(vinyl acetate) or a copolymer thereof claim 2 , a poly(vinyl alcohol) or a copolymer thereof claim 2 , a poly(vinyl acetal) or a copolymer thereof claim 2 , or a polyamide or a copolymer thereof.4: The composition according to claim 1 , wherein{'sup': 4', '6, 'Rand Rare hydrogen,'}{'sup': 5', '7, 'sub': 1', '8, 'Rand Rare independently from each other hydrogen or C-C-alkyl,'}{'sup': P2', 'P6, 'sub': '1', 'Rand Rare independently from each other hydrogen or C-alkyl,'}{'sup': P3', 'P5, 'sub': 1', '4, 'Rand Rare independently from each other hydrogen or C-C-alkyl,'}{'sup': O1', 'O6, 'sub': 1', '8, 'Rand Rare independently from each other hydrogen or C-C- ...

ORGANIC PHOSPHORUS-BASED COMPOUND, AND FLAME RETARDANT AND FLAME-RETARDANT PRODUCT COMPRISING THE SAME

An organic phosphorus-based compound which satisfies the following requirements (i) to (viii) and is represented by the following formula (1): (i) the organic purity should be not lower than 98%; (ii) the solubility in 20° C. water should be not higher than 0.1 g/100 g of water; (iii) the total halogen component content should be not higher than 1,000 ppm; (iv) the total volatile organic matter content should be not higher than 800 ppm; (v) the Δ pH value should be not larger than 1.0; (vi) the volume standard median diameter should be not larger than 30 μm; (vii) the maximum particle diameter should be not larger than 200 μm; and (viii) the standard deviation represented by the following formula should be not larger than 20 μm. Standard deviation=(d84%+d16%)/2; wherein d84%: particle diameter at a point where the cumulative curve becomes 84% (μm), and d16%: particle diameter at a point where the cumulative curve becomes 16% (μm). 3. The organic phosphorus-based compound according to claim 1 , which has (iii) a total halogen component content of not higher than 500 ppm claim 1 , (iv) a total volatile organic matter content of not higher than 500 ppm claim 1 , (v) a Δ pH value of not larger than 0.5 claim 1 , (vi) a volume-standard median diameter of not larger than 20 μm and (vii) a maximum particle diameter of not larger than 150 μm.4. A flame retardant comprising at least 50 wt % of the organic phosphorus-based compound of .5. A flame-retardant product comprising the flame retardant of . The present invention relates to an organic phosphorus-based compound having high flame retardancy and a good appearance, and a flame retardant and a flame-retardant product comprising the same.Polymer materials typified by polycarbonate resin, polyphenylene oxide resin, polyester resin, ABS resin, styrene resin, epoxy resin and polyamide resin are used in a wide variety of fields such as mechanical parts, electric parts and auto parts as molding materials, fiber materials, and ...

3-PHENYL-BENZOFURAN-2-ONE DIPHOSPHATE DERIVATIVES AS STABILIZERS

The invention relates to a composition comprising an organic material susceptible to oxidative, thermal or light-induced degradation and a compound of formula I-P, I-O or I-M. Further embodiments are a compound of formula I-P, I-O or I-M, a process for protection of the organic material by the compound, the use of the compound against degradation of the organic material, an additive composition comprising the compound, processes for manufacturing the compound and an intermediate involved therein. 2. The composition according to claim 1 , wherein the organic material is a polymer claim 1 , an oligohydroxy compound claim 1 , a wax claim 1 , a fat or a mineral oil.3. The composition according to claim 2 , wherein the organic material is a polymer claim 2 , which is a polyolefin or a copolymer thereof claim 2 , a polystyrene or a copolymer thereof claim 2 , a polyurethane or a copolymer thereof claim 2 , a polyether claim 2 , which is obtainable by the polymerization of an epoxide claim 2 , an oxetane or a tetrahydrofuran claim 2 , or a copolymer thereof claim 2 , a polyester or a copolymer thereof claim 2 , a polycarbonate or a copolymer thereof claim 2 , a poly(vinyl chloride) or a copolymer thereof claim 2 , a poly(vinylidene chloride) or a copolymer thereof claim 2 , a polysulfone or a copolymer thereof claim 2 , a poly(vinyl acetate) or a copolymer thereof claim 2 , a poly(vinyl alcohol) or a copolymer thereof claim 2 , a poly(vinyl acetal) or a copolymer thereof claim 2 , or a polyamide or a copolymer thereof.4. The composition according to claim 1 , wherein{'sup': 4', '6, 'Rand Rare hydrogen,'}{'sup': 5', '7, 'sub': 1', '8, 'Rand Rare independently from each other hydrogen or C-C-alkyl,'}{'sup': P2', 'P6, 'sub': '1', 'Rand Rare independently from each other hydrogen or C-alkyl,'}{'sup': P3', 'P5, 'sub': 1', '4, 'Rand Rare independently from each other hydrogen or C-C-alkyl,'}{'sup': O1', 'O6, 'sub': 1', '8, 'Rand Rare independently from each other hydrogen or C-C ...

BIPHENYL TETRADENTATE PHOSPHITE COMPOUND PREPARATION METHOD AND APPLICATION THEREOF

The disclosure relates to chemical synthesis, and more particularly to a biphenyltetradentate phosphite compound and a preparation and application thereof. The compound has a structure of formula(I): 2. A method of preparing the biphenyl tetradentate phosphite compound of claim 1 , comprising:reacting a biphenyl tetraphenol compound with phosphorochloridite in an organic solvent in the presence of n-butyl lithium to produce the biphenyl tetradentate phosphite compound;wherein the phosphorochloridite is selected from L1-L26.3. The method of claim 2 , the step of “reacting a biphenyl tetraphenol compound with phosphorochloridite” comprises:adding the biphenyl tetraphenol compound and the organic solvent to a reactor successively under a nitrogen atmosphere; dropwise adding the n-butyl lithium at a low temperature; and heating the reaction mixture to room temperature followed by reaction under reflux; anddropwise adding a phosphorochloridite solution of the biphenyl, methylene dibenzyl, binaphthyl, benzoyloxy, ortho-phenyl, phenyl, naphthyl or aryl group at low temperature; and reacting the reaction mixture at room temperature followed by concentration to obtain the biphenyl tetradentate phosphite compound.4. The method of claim 3 , wherein the biphenyl tetraphenol compound is prepared by a reaction of 4 claim 3 ,6-di(tert-butyl)benzene-1 claim 3 ,3-diol under the action of a metallic oxidant claim 3 , an acid and a reaction solvent.5. The method of claim 3 , wherein the biphenyl tetraphenol compound is prepared through steps of:dissolving 4,6-di(tert-butyl)benzene-1,3-diol in an acid in a reacting kettle; dropwise adding a metallic oxidant and a reaction solvent; and reacting the reaction mixture at −20-50° C. for 1-12 h followed by filtration to obtain the biphenyl tetraphenol compound; wherein a molar ratio of the metallic oxidant to the 4,6-di(tert-butyl)benzene-1,3-diol is (0.1-1.5):1.6. The method of claim 4 , wherein the acid is selected from the group ...

STABILIZED ORGANOPHOSPHOROUS COMPOUNDS

A hydroformylation process wherein the hydrolyzable organophosphorous ligand component of the catalyst is supplied as a stabilized ligand composition comprising a hydrolyzable organophosphorous ligand and, per 100 moles compound, from 0.05 to 13 acid-neutralizing equivalents of an acid scavenger. 1. A process comprising: (a) contacting CO , H , and at least one olefin in a reaction zone under hydroformylation conditions sufficient to form at least one aldehyde product in the presence of a catalyst comprising , as components , a transition metal and a hydrolyzable organophosphorous ligand , and (b) providing the ligand as a ligand composition comprising the ligand and from 0.05 to 13 acid-neutralizing equivalents of an acid scavenger per 100 moles ligand.2. The process of further comprising claim 1 , prior to providing the ligand composition claim 1 , storing the ligand composition under a substantially oxidizer-free atmosphere claim 1 , under vacuum claim 1 , or both.3. The process of wherein the ligand composition is stored for a period of at least 30 days.4. The process of wherein the total weight of the hydrolyzable organophosphorous ligand and the acid scavenger is at least 50 wt % claim 1 , based on the total weight of the ligand composition.5. The process of wherein the acid scavenger includes at least one compound selected from: triethanolamine (TEA) and ethoxylates thereof claim 1 , methyldiethoxyamine claim 1 , dimethylethoxyamine claim 1 , ethyldiethoxyamine claim 1 , tri-3-propoxyamine claim 1 , tri-(2-(methanol)ethyl)amine claim 1 , tri-isopropanolamine and propoxylates thereof claim 1 , 4-hydroxyl-2 claim 1 ,2 claim 1 ,6 claim 1 ,6-tetramethylpiperidine claim 1 , bis(2 claim 1 ,2 claim 1 ,6 claim 1 ,6-tetramethyl-4-piperidyl) sebacate claim 1 , triethylamine claim 1 , tri-n-propylamine claim 1 , tri-n-butylamine claim 1 , tri-iso-butylamine claim 1 , tri-iso-propylamine claim 1 , tri-n-hexylamine claim 1 , tri-n-octylamine claim 1 , dimethyl-iso- ...

Mixture of different asymmetrical bisophosphites and use thereof as a catalyst mixture in hydroformylation

The invention relates to a mixture of unsymmetric bisphosphites, to a process for preparation thereof, to the reaction thereof with metals to give mixtures comprising complexes of the bisphosphites and the metal, and to the use thereof as a catalytically active composition in hydroformylation reactions, and also to the hydroformylation reaction itself.

CHIRAL IMIDODIPHOSPHATES AND DERIVATIVES THEREOF

The invention relates to chiral imidodiphosphates and derivatives thereof having the general formula I, 116.-. (canceled)21. A chiral imidodiphosphate according to claim 20 , wherein claim 20 , in such formula (III) claim 20 ,{'sup': 1', '4, 'sub': 1', '20', '3', '8', '6', '20', '1', '20', '3', '8', '6', '20, 'Rto R, respectively may each be selected from Cto Cstraight chain, branched chain or cyclic aliphatic hydrocarbons, optionally having one or more unsaturated bonds, C-C-heterocycloalkyl or Cto Caromatic hydrocarbon and partially arene-hydrogenated forms, each hydrocarbon optionally being substituted by one or more groups selected from Cto Cstraight chain, branched chain or cyclic aliphatic hydrocarbons, optionally having one or more unsaturated bonds, C-C-heterocycloalkyl or Cto Caromatic hydrocarbon and partially arene-hydrogenated forms, and'}{'sup': I', 'II', 'III', 'I', 'II', 'III, 'sub': 1', '20', '3', '8', '6', '20', '1', '20', '3', '8', '6', '20, 'W may be selected from hydrogen, halogen, a metal, or a cationic organic group, or a substituted silicon —SiRRR, wherein R, Rand Rmay be same or different and each stand for hydrogen, halogen, Cto Cstraight chain, branched chain or cyclic aliphatic hydrocarbons, optionally having one or more unsaturated bonds, C-C-heterocycloalkyl or Cto Caromatic hydrocarbon and partially arene-hydrogenated forms, each hydrocarbon optionally being substituted by one or more groups selected from Cto Cstraight chain, branched chain or cyclic aliphatic hydrocarbons, optionally having one or more unsaturated bonds, C-C-heterocycloalkyl or Cto Caromatic hydrocarbon and partially arene-hydrogenated forms thereof,'}and its tautomeric and ionic forms, and derivatives thereof.22. A chiral imidodiphosphate according to claim 20 , wherein claim 20 , in such formula (III) claim 20 , (Rand R) and (Rand R) claim 20 , respectively each form a ring structure which may be the same or different and is derived from a bridged claim 20 , ...

EXTRACTION SOLVENT CONTROL FOR REDUCING STABLE EMULSIONS

Disclosed herein are methods for recovering diphosphite-containing compounds from mixtures comprising organic mononitriles and organic dinitriles, using liquid-liquid extraction. Also disclosed are treatments to enhance extractability of the diphosphite-containing compounds. 1. A process for recovering diphosphite-containing compounds from a feed mixture comprising diphosphite-containing compounds , organic mononitriles and organic dinitriles in a multistage countercurrent liquid-liquid extractor with extraction solvent comprising aliphatic hydrocarbon , cycloaliphatic hydrocarbon or a mixture of aliphatic and cycloaliphatic hydrocarbon , said process comprising:a) flowing the feed mixture to the first stage of the multistage countercurrent liquid-liquid extractor; and 'wherein the first stage of the multistage countercurrent liquid-liquid extractor comprises a mixing section and a settling section, wherein a light phase separates from a heavy phase in the settling section, wherein the light phase comprises extraction solvent and extracted diphosphite-containing compounds, wherein the heavy phase comprises organic mononitriles and organic dinitriles, wherein a first portion of the light phase is withdrawn from the settling section and treated to recover diphosphite-containing compounds extracted into the light phase, and wherein a second portion of the light phase is withdrawn from the settling section and recycled to the mixing section of the first stage of the multistage countercurrent liquid-liquid extractor.', 'b) contacting the feed mixture with extraction solvent in the multistage countercurrent liquid-liquid extractor,'}2. The process of claim 1 , wherein the recycle of the light phase to the mixing section of the first stage of the multistage countercurrent liquid-liquid extractor is sufficient to result in enhanced settling of the light phase and heavy phase in the settling section of the first stage.3. The process of claim 1 , wherein the recycle of the ...

Novel Compounds

A compound of Formula (I) wherein Y 1 , Y 2 , X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , and R 9 are as defined herein; and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Mixtures of constitutionally isomeric bisphosphites

The invention relates to mixtures of constitutional isomer bisphosphites of formulae (1a) and (2a), to a method for the production thereof, to the reaction thereof with metals to form mixtures containing complex compounds of the constitutional isomer bisphosphites of formulae (1a) and (2a) and the metal, and to the use thereof as a catalytically active composition in hydroformylation reactions. Said hydroformylactically active compositions comprises, in addition to the complex compounds of metal and the constitutional isomer bisphosphites of formulae (1a) and (2a), non-bound bisphosphites of the constitutional isomer bisphosphites of formulae (1a) and (2a) and at least one additional component.

DOPO DERIVATIVE FLAME RETARDANTS

The present invention relates to novel, halogen-free flame retardant derived from 9,10-Dihydro-9-Oxa-10-Phosphaphenantrene-10-oxide (DOPO). This invention also relates to the use of the halogen free DOPO derived flame retardant in polymers. 2. A composition comprising the compound of claim 1 , wherein said composition has an unreacted DOPO concentration of less than about 50 claim 1 ,000 ppm.3. A composition comprising the compound of claim 1 , wherein said composition has a solvent concentration less than about 1 claim 1 ,000 ppm.4. A composition comprising the compound of claim 1 , wherein the amount of said compound in the composition is greater than about 95 wt %.5. A composition comprising the compound of claim 1 , wherein said composition has a 5% TGA weight loss at a temperature of greater than about 245° C.6. A composition comprising the compound of claim 1 , wherein said composition has a total chlorine or bromine concentration less than about 1000 ppm. The present invention relates to novel, halogen-free flame retardant derived from 9,10-Dihydro-9-Oxa-10-Phosphaphenantrene-10-oxide (DOPO). This invention also relates to the use of the halogen free DOPO derived flame retardant in polymers.Polymers as a class of materials are generally flammable. Owing to their combustibility, thermoplastic and thermoset polymers, for example polyamides, polyesters, epoxy resins and polyurethanes, require the use of flame retardants fir many applications, Typically, halogenated compounds, more specifically, aromatic polybronunated compounds, have been used as flame retardant additives in polymers. It is generally accepted that these products inhibit radical gas phase reactions from occurring in the flame when these products are ignited. This makes halogenated flame retardants very commonly used additives for different types of polymeric materials. However, during the last fifteen years or so, halogenated flame retardants have come under scrutiny because of ecological ...

BISPHOSPHITES HAVING AN UNSYMMETRIC OUTER BIPHENOL UNIT

Bisphosphites having at least one unsymmetric outer biphenol unit are useful for the hydroformylation of an olefin. 2. The compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R, R, R, R, R, R, R, Rare each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, —(C-C)-alkyl, —O—(C-C)-alkyl, —O—(C-C)-aryl, —S-alkyl, and —S-aryl.'}3. The compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R, R, R, R, R, R, R, Rare each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, —(C-C)-alkyl, —O—(C-C)-alkyl, and —O—(C-C)-aryl.'}4. The compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R″, R″, R″, R″, R″, R″, R″, R″ are each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, and —(C-C)-alkyl, —O—(C-C)-alkyl, and —O—(C-C)-aryl.'}5. The compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R, R, R, R, R, R, R, Rare each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, —(C-C)-alkyl, —O—(C-C)-alkyl, and —O—(C-C)-aryl.'}6. The compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R″, R′, R′, R′, R′, R′, R′, R′ are each independently selected from the group consisting of{'sub': 1', '12', '1', '12', '6', '20, '—H, —(C-C)-alkyl, —O—(C-C)-alkyl, and —O—(C-C)-aryl.'}7. The compound according to claim 1 ,{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'wherein R″, R″, R″, R″, R″, R″, R″, R″ are each independently selected from the group consisting of{'sub': 6', '20, '—H, and —O—(C-C)-aryl.'}8. The compound according to claim 1 ,{'sup': 1', '1', '1, 'wherein R, R′ and R″ are the same radical; and'}{'sup': 8', '8', '8, 'R, R′ and R″ are the same radical.'}9. The compound according to claim 1 ,{'sup': 1', '8, 'wherein R′ and R′ are not the same radical; and'}{' ...

EXTRACTION SOLVENT CONTROL FOR REDUCING STABLE EMULSIONS

Disclosed herein are methods for recovering diphosphite-containing compounds from mixtures comprising organic mononitriles and organic dinitriles, using liquid-liquid extraction. Also disclosed are treatments to enhance extractability of the diphosphite-containing compounds. 1. A process for recovering diphosphite-containing compounds from a feed mixture comprising diphosphite-containing compounds , organic mononitriles and organic dinitriles in a multistage countercurrent liquid-liquid extractor with extraction solvent comprising aliphatic hydrocarbon , cycloaliphatic hydrocarbon or a mixture of aliphatic and cycloaliphatic hydrocarbon , said process comprising:a) flowing the feed mixture to the first stage of the multistage countercurrent liquid-liquid extractor; and 'wherein the first stage of the multistage countercurrent liquid-liquid extractor comprises a mixing section and a settling section, wherein the mixing section provides a mixed phase comprising a light phase and a heavy phase, wherein a light phase separates from a heavy phase in the settling section, wherein a mixed phase comprising a heavy phase, light phase is present in the settling section between the light phase and the heavy phase, wherein the light phase comprises extraction solvent and extracted diphosphite-containing compounds, wherein the heavy phase comprises organic mononitriles and organic dinitriles, wherein at least a portion of the light phase is withdrawn from the settling section and treated to recover diphosphite-containing compounds extracted into the light phase, wherein a first portion of the heavy phase is passed to the second stage of the multistage countercurrent liquid-liquid extractor, and wherein a second portion of the heavy phase is withdrawn from the settling section of the first stage of the multistage countercurrent liquid-liquid extractor and recycled to the settling section of the first stage of the multistage countercurrent liquid-liquid extractor.', 'b) contacting ...

PRODRUG COMPOUNDS AND USES THEROF

Provided herein are cyclic phosphorus-containing prodrug compounds, their preparation and their uses, such as treating diseases via modulating molecular targets in the liver. 2. The compound of claim 1 , wherein M is a nucleoside antiviral or anticancer agent.3. The compound of claim 1 , wherein M is a lipid modulator.4. The compound of claim 1 , wherein M is a nuclear hormone receptor modulator.5. The compound of claim 1 , wherein M is at least one selected from the group consisting of: a HCV polymerase inhibitor claim 1 , a reverse transcriptase inhibitor claim 1 , a DNA synthesis inhibitor claim 1 , an RNA synthesis inhibitor claim 1 , and an antimetabolic agent.7. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable excipient.8. A method of treating a disease claim 1 , disorder or condition in the liver of a subject comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering an effective amount of a compound of to a subject in need thereof.'}9. A method of treating a disease claim 1 , disorder or condition by intervening in a molecular pathway or target in the liver in a subject comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering an effective amount of a compound of to a subject in need thereof.'}10. A method of treating a disease claim 1 , disorder or condition in the liver or a disease claim 1 , disorder or condition in which the physiological or pathogenic pathways involve the liver in a subject claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering an effective amount of a compound of to the subject.'}11. The method of claim 8 , wherein the disease claim 8 , disorder or condition is selected from the group consisting of hepatitis claim 8 , liver cancer claim 8 , liver fibrosis claim 8 , malaria claim 8 , viral infection claim 8 , parasitic infection claim 8 , cancer claim 8 , fatty liver claim 8 , diabetes claim 8 , hyperlipidemia claim 8 , ...

PURIFYING ORGANOPHOSPHORUS COMPOUNDS CONTAMINATED WITH CHLORINE

The invention relates to a process for the purification of a contaminated organophosphorus product which comprises at least one organophosphorus compound and, as contaminant, at least one chlorine compound. It is based on the object of indicating a purification method in which the chlorine content of an organophosphorus product which comprises at least one organophosphorus compound and at least one chlorine compound as contaminant, can be reduced from originally 1000 to 100 000 ppm to a total chlorine content between 10 ppm and 10 000 ppm. This is achieved by a process with the steps: 115-. (canceled)16. A process for the purification of a contaminated organophosphorus product which comprises at least one organophosphorus compound and , as contaminant , at least one chlorine compound , having the following steps:a) providing the contaminated organophosphorus product;b) completing dissolution of the contaminated organophosphorus product in a solvent to give a contaminated solution;c) separating the contaminated solution by means of a filter and/or by means of a membrane separation unit to give a purified solution;d) removing the solvent from the purified solution to give a purified organophosphorus product.17. The process according to claim 16 , in which the stepsa) providing the contaminated organophosphorus product;andb) completing dissolution of the contaminated organophosphorus product in a solvent to give a contaminated solution;take place in one operation by providing the contaminated organophosphorus product completely dissolved in the contaminated solution.18. The process according to claim 16 , wherein the total chlorine content of the purified solution is less than that of the total chlorine content of the contaminated solution.19. The process according to claim 18 , wherein the total chlorine content of the contaminated organophosphorus product is between 1000 ppm and 100 claim 18 ,000 ppm claim 18 , and that the total chlorine content of the purified ...

SPIRO BISPHOSPHITE BASED COMPOUND AND USES OF THE SAME

A Spiro bisphosphite based compound and its uses are disclosed. The compound is represented by the following Formula VII′:

PHOSPHOROAMIDATE ESTERS, AND USE AND SYNTHESIS THEREOF

Phosphoramidate esters and related nucleotide analogs useful in polynucleotide sequencing techniques, and synthetic methods for preparing those compounds, are disclosed. These compounds include nucleotide phosphoramidates analogs that are modified on the alpha-phosphate to enable attachment of a variety of application-specific substituents such as tether molecules.

COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING

The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.

Composite Phosphorus Flame Retardant Comprising Cyclic Organophosphate With Multiple DOPO Moieties And Preparation Method Thereof

The present invention discloses a composite phosphorus flame retardant comprising cyclic organophosphate with multiple DOPO moieties, and a manufacturing method thereof. The composite structure phosphorus flame retardant has a structural formula comprising at least one organophosphate and at least two DOPO cyclic organophosphates. The method comprises: mixing the DOPO with a polyhydroxy alkane or a hydrocarbon substituent, wherein the polyhydroxy alkane has at least three hydroxy groups, and the hydrocarbon substituent has a chain with at least three carbon atoms; heating the mixture to 195-210° C. and reacting for 14-17 hours in the presence of a protective gas, and then cooling to room temperature; adding a phosphorus oxohalide or an incompletely esterified phosphorus oxohalide; and heating to 55-65° C. and reacting for 1.5-3 hours, then cooling to room temperature to obtain the product. The invention provides flame retardation at two decomposition temperatures, the first occurring within a range of 230-310° C., while the other occurring after 345° C. The in has a simple composition, is easy to use, has high phosphorus contents, and provides improved flame retardance. 1. A composite phosphorus flame retardant comprising cyclic organophosphate with multiple DOPO moieties , wherein ,the composite phosphorus flame retardant has a structural formula comprising at least one organophosphate and at least two DOPO cyclic organophosphates.3. A preparation method of a composite phosphorus flame retardant comprising cyclic organophosphate with multiple DOPO moieties , comprising the following steps:Step (1) mixing the DOPO with a polyhydroxy alkane or a hydrocarbon substituent, wherein the polyhydroxy alkane has at least three hydroxy groups, and the hydrocarbon substituent has a chain with at least three carbon atoms;heating the mixture to 195-210° C. and reacting for 14-17 hours in presence of a protective gas, so that at least one hydroxy group therein does not ...

Improved hydroformylation process

An improved rhodium-organophosphite complex catalyzed hydroformylation process, the improvement comprising carrying out said process in the presence of a catalytic activity enhancing additive said additive being selected from the class consisting of added water, a weakly acidic compound, or both added water and a weakly acidic compound.

ASYMMETRIC SYNTHESIS.

ESTA INVENCION ES RELATIVA A SINTESIS ASIMETRICA EN LA CUAL UN COMPUESTO PROQUIRICO O QUIRICO ESTA CONECTADO EN LA PRESENCIA DE UN COMPLEJO CATALIZADOR LIGANTE CTIVO PARA PRODUCIR UN PRODUCTO OPTICAMENTE ACTIVO. THIS INVENTION IS RELATIVE TO ASYMMETRICAL SYNTHESIS IN WHICH A PROQUIRIC OR CHIRICAL COMPOUND IS CONNECTED IN THE PRESENCE OF A LIGATING CATALYST COMPLEX TO PRODUCE AN OPTICALLY ACTIVE PRODUCT.

METHOD OF HYDROFORMILATION WITH THE USE OF MULTI-STAGE REACTORS

Это изобретение касается процесса получения одного или более продуктов в многоступенчатом реакторе, имеющем более одной реакционной ступени; этот процесс включает реакцию в указанном многоступенчатом реакторе одного или более реагентов с монооксидом углерода в присутствии катализатора на основе комплекса металла с фосфорорганическим лигандом и, возможно, свободного фосфорорганического лиганда с получением указанных одного или более продуктов, в котором указанный катализатор на основе комплекса металла с фосфорорганическим лигандом не подвергается существенной дезактивации в присутствии только монооксида углерода, и/или его селективность по продукту нормального строения изменяется менее чем на 0,2% продукта нормального строения на 1 фунт/кв.дюйм парциального давления монооксида углерода, и/или скорость реакции изменяется менее чем на 2% на 1 фунт/кв.дюйм парциального давления монооксида углерода.Международная заявка была опубликована вместе с отчетом о международном поиске. This invention relates to the process of obtaining one or more products in a multi-stage reactor having more than one reaction stage; this process involves the reaction in the specified multi-stage reactor of one or more reactants with carbon monoxide in the presence of a catalyst based on a complex of metal with an organophosphorus ligand and, possibly, of a free organophosphorus ligand with the production of said one or more products, the ligand does not undergo substantial deactivation in the presence of carbon monoxide only, and / or its selectivity for the product is normal It changes by less than 0.2% of a normal product by 1 psi of carbon monoxide partial pressure, and / or the reaction rate changes by less than 2% by 1 psi of carbon monoxide partial pressure. The international application was published with the international search report.

Macromolecular antioxidants based on stξrically hindered phenolic phosphites

Sterically hindered phenol and phosphite based compounds, represented by a formula selected from (I-III), in and their use as antioxidants in a wide range of materials including, but not limited to, food, plastics, elastomers, composites and petroleum based products is disclosed herein.

Nuevos bisfenolfosfitos de cicloalquilideno

Se describen nuevos compuestos de la fórmula (I) en la cual N representa 0,1 '0 2, R y R1, independientemente entre ellos, significan alquilo de C1 a C4 o conjuntamente representan un radical 2,3-dehidro-pentametileno, R2, R3, independientemente entre ellos, significan hidrógeno, alquilo de C1 a C4 o cicloalquilo de C5 a C6, y R4, R5, R6 y R7, en el caso de que n sea 1, independientemente entre ellos, representan hidrógeno o alquilo de C1 a C4, en el caso de que n sea 0 y n sea 2, representan hidrógeno, en calidad de estabilizadores para materiales orgánicos, contra la degradación térmica, oxidante o inducida por la luz.

Cycloalkylidene bisphenol phosphites

Novel compounds of the formula I <IMAGE> in which n is 0, 1 or 2, R and R1 independently of one another are C1-C4-alkyl or together are a 2,3-dehydropentamethylene radical, R2 and R3 independently of one another are hydrogen, C1-C4-alkyl or C5-C6-cycloalkyl, and R4, R5, R6 and R7, in the event that n = 1, independently of one another are hydrogen or C1-C4-alkyl, and, in the event that n = 0 and in the event that n = 2, are hydrogen, are described as stabilisers for organic materials against thermal, oxidative or light-induced degradation.

BISPHOSPHITE MIXING AND ITS USE AS A CATALYZING MIXTURE IN HYDROFORMILATION

Mezcla de bisfosfitos, un procedimiento para su preparación, así como su reacción con metales en compuestos complejos que contienen mezclas de los bisfosfitos isoméricos constitucionales y el metal, así como a su uso como composición catalíticamente activa en reacciones de hidroformilación, como también la reacción de hidroformilación propiamente dicha. Reivindicación 1: Mezcla que comprende los compuestos (1) y (2), en donde R¹ está seleccionado de -Me, -tBu, -OMe; R² está seleccionado de -Me, -tBu, -OMe; R³ está seleccionado de -Me, -tBu, -OMe; R⁴ está seleccionado de -Me, -tBu, -OMe; siempre que, para el caso de que R¹ sea R³, R² no sea igual a R⁴, para el caso de que R² sea R⁴, R¹ no sea igual a R³, y P puede generar otros enlaces. Reivindicación 16: Procedimiento para la hidroformilación de compuestos insaturados y sus mezclas usando: de una composición de acuerdo con una de las reivindicaciones 12 ó 13 y de una mezcla gaseosa que comprende monóxido de carbono e hidrógeno. Mixture of bisphosphites, a process for their preparation, as well as their reaction with metals in complex compounds containing mixtures of constitutional isomeric bisphosphites and metal, as well as their use as a catalytically active composition in hydroformylation reactions, as well as the reaction of hydroformylation itself. Claim 1: Mixture comprising the compounds (1) and (2), wherein R¹ is selected from -Me, -tBu, -OMe; R² is selected from -Me, -tBu, -OMe; R³ is selected from -Me, -tBu, -OMe; R⁴ is selected from -Me, -tBu, -OMe; provided that, in case R que is R³, R² is not equal to R⁴, in case R² is R⁴, R¹ is not equal to R³, and P can generate other links. Claim 16: Process for the hydroformylation of unsaturated compounds and mixtures thereof using: of a composition according to one of claims 12 or 13 and of a gas mixture comprising carbon monoxide and hydrogen.

Bis-phosphate compound and asymmetric reaction using the same

A novel bis-phosphate compound is provided which can be applied to a wide range of reactive substrates and reactions as an asymmetric reaction catalyst and can realize an asymmetric reaction affording a high yield and a high enantiomeric excess. The bis-phosphate compound has a tetraaryl skeleton represented by General Formula (1). In an asymmetric reaction, an amidodiene and an unsaturated aldehyde compound are reacted with each other in the presence of the optically active bis-phosphate compound to give an optically active amidoaldehyde. The invention allows a reaction such as an asymmetric Diels-Alder reaction to proceed efficiently, which has been difficult with conventional mono-phosphate compounds. Thus, the invention enables an industrially feasible method for the production of optically active amidoaldehydes, optically active β-amino acid derivatives, optically active diamine compounds, optically active pyrrolidine derivatives and optically active dihydropyran derivatives which are useful as products such as medicines, agricultural chemicals and chemical products as well as synthesis intermediates for such products.

Improved hydroformylation process

二烯烃的氢氰化和非共轭2-烷基-3-单烯烃腈的异构化

本发明涉及一种用于将二烯烃化合物氢氰化以制备非共轭非环状腈的改进的液相方法，并且还涉及用于将所述腈异构化的液相方法，所述腈包括3－和/或4－单烯烃直链腈。其改进在于本发明方法是在零价镍和多齿亚磷酸酯配体存在下进行。本发明还公开了新的多齿亚磷酸酯配体和由此制备的催化剂前体组合物。

用于二烯烃的氢氰化和非共轭2－烷基－3－单烯烃腈的异构化的多齿亚磷酸酯配体和镍催化剂组合物

本发明提供了用于二烯烃的氢氰化和非共轭2-烷基-3-单烯烃腈的异构化的改进的多齿亚磷酸酯配体和由其制备的镍催化剂前体组合物。

Process for the preparation of bisphosphites

Verfahren zur Herstellung von Bisphosphiten der Formel I mit R 1 , R 2 , R 3 , R 4 = H, aliphatischer, alicyclischer, aliphatisch-alicyclischer, heterocyclischer, aliphatisch-heterocyclischer, aromatischer, aromatisch-aromatischer, aliphatisch-aromatischer Kohlenwasserstoffrest mit 1 bis 50 Kohlenstoffatomen, F, Cl, Br, I, -CF 3 , -OR 7 , -COR 7 , -COR 7 , -SR 7 , -SOR 7 , -SOR 7 , -SO 3 R 7 , wobei R 1 bis R 4 eine gleiche oder unterschiedliche Bedeutung besitzen und kovalent miteinander verknüpft sein können, R 7 = substituierter oder unsubstituierter, aliphatischer oder aromatischer Kohlenwasserstoffrest mit 1 bis 25 Kohlenstoffatomen, mit gleicher oder unterschiedlicher Bedeutung, Q = zweiwertiger aliphatischer, alicyclischer, aliphatisch-alicyclischer, heterocyclischer, aliphatisch-heterocyclischer, aromatischer, aliphatisch-aromatischer Kohlenwasserstoffrest mit 1 bis 50 Kohlenstoffatomen, Z, Y = Cl, Br, I W, X = aliphatische, alicyclische, aliphatisch-alicyclische, heterocyclische, aliphatisch-heterocyclische, aromatische, aromatisch-aromatische, aliphatisch-aromatische Kohlenwasserstoffreste mit 1 bis 50 Kohlenstoffatomen, die gleich oder unterschiedlich oder kovalent miteinander verknüpft sein können, wobei die Reaktionssequenz durchgeführt wird, dadurch gekennzeichnet, dass die Reaktionsschritte a), b) und c) in aprotischen und unpolaren... Process for the preparation of bisphosphites of formula I. with R 1 , R 2 , R 3 , R 4 = H, aliphatic, alicyclic, aliphatic-alicyclic, heterocyclic, aliphatic-heterocyclic, aromatic, aromatic-aromatic, aliphatic-aromatic hydrocarbon radical having 1 to 50 carbon atoms, F, Cl, Br , I, -CF 3 , -OR 7 , -COR 7 , -COR 7 , -SR 7 , -SOR 7 , -SOR 7 , -SO 3 R 7 , where R 1 to R 4 have the same or different meaning and can be covalently linked, R 7 = substituted or unsubstituted, aliphatic or aromatic hydrocarbon radical with 1 to 25 carbon atoms, with the same or different meaning, Q = divalent aliphatic, alicyclic, aliphatic- ...

Verfahren zur Herstellung von dreiwertigen Organophosphor-Verbindungen

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von Organophosphiten, Organophosphoniten und Organophosphiniten durch Kondensation von Phosphortrihalogeniden oder Organophosphorhalogeniden mit organischen, Hydroxy-Gruppen tragenden Verbindungen in Gegenwart von polymeren basischen Ionentauscherharzen. DOLLAR A Durch das erfindungsgemäße Verfahren ist die Herstellung von dreiwertigen Organophosphor-Verbindungen, welche z. B. als Liganden in Rhodiumkomplexen verwendet werden können, die als Katalysator in der Hydroformylierung eingesetzt werden können, einfach möglich.

Process for the preparation of organoacyl phosphites

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von Organophosphiten, Organophosphoniten und Organophosphiniten durch Kondensation von Phosphortrihalogeniden oder Organophosphorhalogeniden mit organischen, Hydroxy-Gruppen tragenden Verbindungen in Gegenwart von polymeren basischen Ionentauscherharzen. DOLLAR A Durch das erfindungsgemäße Verfahren ist die Herstellung von dreiwertigen Organophosphor-Verbindungen, welche z. B. als Liganden in Rhodiumkomplexen, welche als Katalysator in der Hydroformylierung eingesetzt werden können, einfach möglich. The present invention relates to a process for the preparation of organophosphites, organophosphonites and organophosphinites by condensation of phosphorus trihalides or organophosphorus halides with organic, hydroxy-bearing compounds in the presence of polymeric basic ion exchange resins. DOLLAR A By the process according to the invention, the preparation of trivalent organophosphorus compounds which z. As ligands in rhodium complexes, which can be used as a catalyst in the hydroformylation, easily possible.

Mixture of constitutional isomer bisphosphites

본 발명은 하기 화학식 1a 및 2a의 구조 이성질체 비스포스파이트의 혼합물, 그의 제조 방법, 화학식 1a 및 2a의 구조 이성질체 비스포스파이트 및 금속의 착물 화합물을 함유하는 혼합물을 형성하기 위한 금속과의 그의 반응, 및 히드로포르밀화 반응에서 촉매적으로 활성인 조성물로서의 그의 용도에 관한 것이다. 상기 히드로포르밀화 활성 조성물은 금속 및 화학식 1a 및 2a의 구조 이성질체 비스포스파이트의 착물 화합물 외에도, 화학식 1a 및 2a의 구조 이성질체 비스포스파이트의 비결합 비스포스파이트 및 하나 이상의 추가의 성분을 포함한다. <화학식 1a> <화학식 2a> The invention relates to a mixture of the structural isomeric bisphosphites of the general formula (1a) and (2a), a process for its preparation, its reaction with a metal to form a mixture containing the structural isomer bisphosphites of the general formula (Ia) And their use as a catalytically active composition in a hydroformylation reaction. The hydroformylation active composition comprises unconjugated bisphosphite of the structural isomer bisphosphite of formula (Ia) and (2a) and one or more additional components in addition to the complex compounds of the structural isomer bisphosphite of the formula (Ia) and (IIa). <Formula 1a> &Lt; EMI ID =

Hydrolytically stable pentaerythritol diphosphites

A class of hydrolytically stable bis(aralkylphenyl)pentaerythritol diphosphites is disclosed, which is suitable as an antioxidant additives in polyolefins, particularly, in polypropylene. The diphosphites are of low volatility, have a high thermal decomposition temperature and resist yellowing when blended into a polyolefin base. A preferred diphosphite is bis(2,4-dicumylphenyl)pentaerythritol diphosphite.

Hydrolytically stable pentaerythritol diphosphites

A class of hydrolytically stable bis(aralkylphenyl)pentaerythritol diphosphites is disclosed, which is suitable as an antioxidant additives in polyolefins, particularly, in polypropylene. The diphosphites are of low volatility, have a high thermal decomposition temperature and resist yellowing when blended into a polyolefin base. A preferred diphosphite is bis(2,4-dicumylphenyl)pentaerythritol diphosphite.

双磷酸化合物及使用其的不对称反应

本发明涉及双磷酸化合物及使用其的不对称反应，本发明的目的在于提供新颖的双磷酸化合物，其作为不对称反应的催化剂可适用于广泛的反应底物及反应中，可实现高收率和高不对称收率的不对称反应。本发明涉及具有通式(1)所示的四芳基骨架的双磷酸化合物。本发明涉及在该光学活性双磷酸化合物的存在下使酰胺二烯类与不饱和醛化合物发生反应来得到光学活性氨基醛类的不对称反应。由于可利用现有的单磷酸化合物效率良好地进行难以进行的不对称狄尔斯-阿尔德反应等，因而可利用能够在工业上实用化的方法来制造作为医药、农药和化学品等及其合成中间体有用的光学活性氨基醛类、光学活性β-氨基酸衍生物、光学活性二胺化合物、光学活性吡咯烷衍生物和光学活性二氢吡喃衍生物。

Process for manufacture of pentaerythritol diphosphites

A method is disclosed for the production of pentaerythritol diphosphites of high spiro isomer content. The pentaerythritol diphosphites are produced via sequential transesterification of pentaerythritol with a monophosphite followed by a substituted phenol or other alcohol, wherein the transesterification reactions are carried out under controlled conditions of temperature and pressure. The unique reaction conditions result in intermediate and final pentaerythritol diphosphites of high spiro isomer content and high total yield of the diphosphites.

Phosphor, Arsenic And Antimony Compounds Based Upon Diaryl-anellated Bicyclo[2.2.n] Parent Substances And Catalysts Containing Same

인, 비소 및 안티몬의 신규 화합물들을 리간드로 사용하여 8 족의 전이 금속 착물을 형성할 수 있으며, 이들은 히드로포르밀화 반응, 히드로시안화 반응, 카르보닐화 반응, 수소화 반응, 올레핀 올리고머화 반응 및 올레핀 중합 반응, 그리고 복분해 반응(metathesis)을 위한 촉매로서 사용될 수 있다. New compounds of phosphorus, arsenic and antimony can be used as ligands to form Group 8 transition metal complexes, which are hydroformylation, hydrocyanation, carbonylation, hydrogenation, olefin oligomerization and olefin polymerization Reactions, and can be used as catalysts for metathesis. 인, 비소 및 안티몬 화합물, 리간드, 8 족의 전이 금속 착물, 히드로포르밀화 반응, 히드로시안화 반응, 카르보닐화 반응. Phosphorus, arsenic and antimony compounds, ligands, transition metal complexes of Group 8, hydroformylation reactions, hydrocyanation reactions, carbonylation reactions.

Selective synthesis of organodiphosphite compounds

A process for the preparation of organodiphosphites of the formula (ORO)P(OZO)P(ORO) wherein R and Z are different substituted or unsubstituted aryl groups.

双螯合配体及其在羰基化方法中的用途

一种特征为通式I的新颖双螯合组合物，其中M是VB族元素；R 1 和R 2 每个独立地选自氢和单价烃基；或者，R 1 和R 2 键合在一起以形成双基，或者，R 1 和R 2 之一是氢或单价烃基，而R 1 和R 2 的另一个是键合到芳基Ar中的原子的烃基；Ar选自1，2－亚芳基；Q选自1，2－亚芳基、2，2′－双亚芳基和烷基双基；W选自II，III，IV，或V：其中M如上文所定义；每个R独立地选自氢和单价烃基；X选自烷基和芳基双基；Ar 1 和Ar 2 每个独立地选自1，2－亚芳基；Ar 3 和Ar 4 每个独立地选自单价芳基；和通式IV中的n是0或1。组合物可用于在羰基化方法的催化剂中作为配体。

Process for the preparation of hydrolysis-stable organic phosphits

내용 없음. No content.

Chiral di- and triphosphites

The invention claims chiral di- and triphosphites of general formulas (I) or (II), which are bridged by suitable groups. The claimed compounds can be used in asymmetric transition metal catalysis and as chiral transition metal catalysts.

Process for manufacture of pentaerythritol diphosphites

스파이로 이성질체가 고함량 함유되어 있는 펜타에리트리톨 디포스파이트의 제조 방법이 기재되어 있다. 상기 펜타에리트리톨 디포스파이트는, 펜타에리트리톨을 모노포스파이트, 이어서 치환 페놀 또는 알코올과 순차적으로 트랜스에스테르화 반응시킴으로써 제조되는데, 상기 트랜스에스테르화 반응은 온도와 압력이 조절된 조건하에서 수행된다. 상기 독특한 반응 조건에 의하여 스파이로 이성질체 함량이 높은 중간체와 최종 생성물이 생성되고, 또 디포스파이트의 총수율이 높게 되는 결과로 된다. A method for producing pentaerythritol diphosphite containing a high content of spiro isomers is described. The pentaerythritol diphosphite is prepared by sequentially transesterifying pentaerythritol with a monophosphite, followed by a substituted phenol or alcohol, wherein the transesterification reaction is performed under controlled conditions of temperature and pressure. The unique reaction conditions result in the formation of intermediates and end products having a high isomer content as a spy and a high yield of dephosphite. 펜타에리트리톨 디포스파이트, 스파이로 이성질체, 트랜스에스테르화 반응 Pentaerythritol diphosphite, spiro isomer, transesterification reaction

合成二亚磷酸酯的淤浆方法

本发明提供用于制备二亚磷酸酯的逐步方法。在步骤(a)中，所述方法通过如下步骤以高收率制备一氯代亚磷酸酯：使三氯化磷与芳族二醇在淤浆中、在反应条件下并且在第二芳族二醇存在下接触，以产生包含一氯代亚磷酸酯、第二芳族二醇、和过量PCl3的混合物。所述淤浆包含小于5摩尔％的氮碱，并且选择有机溶剂以使其具有低氯化氢溶解度。在除去过量PCl3以后，添加氮碱以实现一氯代亚磷酸酯与第二芳族二醇的缩合，得到二亚磷酸酯。本发明特别提供通过以上路线制备6，6′-(3，3′，5，5′-四-叔丁基联苯-2，2′-二基)双(氧)双二苯并[d，f][1，3，2]二氧杂磷杂环庚烯的方法。

Supported bis(phosphorus) ligands

SUPPORTED BIS (PHOSPHORUS) LIGANDS ARE DISCLOSED FOR USE IN A VARIETY OF CATALYTIC PROCESSES, INCLUDING THE HYDROCYANATION OF UNSATURATED ORGANIC COMPOUNDS. CATALYSTS ARE FORMED WHEN THE LIGANDS ARE COMBINED WITH A CATALYTICALLY ACTIVE METAL (E.G., NICKEL).

Tetraoxa diphosphaspiro compounds

The present disclosure provides tetraoxa diphosphaspiro compound represented by Formula I. which is capable of stabilizing polymers. Wherein in formula I, R1 and R2 are represented by at least one fragment selected from the group consisting of formula Ia and Ib, wherein; R3 is at least one selected from the group consisting of hydrogen, C1-C10 substituted or unsubstituted, linear or branched alkyl group and aryl group, preferably C1 unsubstituted alkyl group; R4 is at least one selected from the group consisting of C1-C10 substituted or unsubstituted, linear or branched alkyl group and aryl group, preferably C1 unsubstituted alkyl group; and indicates the point of attachment. The present disclosure further provides a process for synthesizing the compound represented by formula 1.

Pentaerythritol diphosphite stabilizers and process

Pentaerythritol diphosphites corresponding to the formula <IMAGE> being useful for stabilizing organic materials against thermal, oxidative and actinic degradation and a process for the preparation thereof.

Process for manufacture of pentaerythritol diphosphites

A method is disclosed for the production of pentaerythritol diphosphites of high spiro isomer content. The pentaerythritol diphosphites are produced via sequential transesterification of pentaerythritol with a monophosphite followed by a substituted phenol or other alcohol, wherein the transesterification reactions are carried out under controlled conditions of temperature and pressure. The unique reaction conditions result in intermediate and final pentaerythritol diphosphites of high spiro isomer content and high total yield of the diphosphites.

Process for manufacture of pentaerythritol diphosphites

A method is disclosed for the production of pentaerythritol diphosphites of high spiro isomer content. The pentaerythritol diphosphites are produced via sequential transesterification of pentaerythritol with a monophosphite followed by a substituted phenol or other alcohol, wherein the transesterification reactions are carried out under controlled conditions of temperature and pressure. The unique reaction conditions result in intermediate and final pentaerythritol diphosphites of high spiro isomer content and high total yield of the diphosphites.

Novel phosphite compounds and the metal complexes thereof

本发明涉及具有下式I或II的亚磷酸酯和它们的金属配合物，它们的制备和所述亚磷酸酯作为催化反应中的配位体的应用，特别是在烯烃的加氢甲酰基化方法中。

Process using multistage reactors

本发明涉及在含有多于一个反应级的一种分级反应器中生产一种或一种以上产品的方法，它包括：在所述分级反应器中；以及在一种金属—有机磷配体络合物催化剂和可选的游离有机磷配体存在下；将一种或一种以上的反应物和一氧化碳反应，生产所述一种或一种以上的产品，其中所述金属—有机磷配体络合物催化剂在只有一氧化碳的存在下，不会发生本质上的减活化；和(或者)一氧化碳分压每改变1磅/英寸 2 ，正常产品选择性变化小于0.2%，和(或者)一氧化碳分压每改变1磅/英寸 2 ；反应速率变化小于2%。

Purification process

公开了一种降低在催化剂制备中使用的配体中的污染物金属水平的方法。

CYCLIC PURINE DINUCLEOTIDES AS STING MODULATORS

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2020 113 165 A (51) МПК C07H 21/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2020113165, 01.12.2016 Приоритет(ы): (30) Конвенционный приоритет: (72) Автор(ы): АДАМС, Джерри Лерой (US), ДАФФИ, Кевин Дж. (US), ЛЯНЬ, Ицянь (US) A Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, стр. 3, ООО "Юридическая фирма Городисский и Партнеры" (54) ЦИКЛИЧЕСКИЕ ПУРИНОВЫЕ ДИНУКЛЕОТИДЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ STING R U Соединение формулы (I) A 2 0 2 0 1 1 3 1 6 5 (57) Формула изобретения 2 0 2 0 1 1 3 1 6 5 (43) Дата публикации заявки: 09.06.2020 Бюл. № 16 R U 03.12.2015 US 62/262,668; 24.02.2016 US 62/299,253; 25.02.2016 US 62/299,704; 26.04.2016 US 62/327,579; 06.05.2016 US 62/332,517 (62) Номер и дата подачи первоначальной заявки, из которой данная заявка выделена: 2018103881 01.02.2018 (71) Заявитель(и): ГЛЭКСОСМИТКЛАЙН ИНТЕЛЛЕКЧУАЛ ПРОПЕРТИ ДИВЕЛОПМЕНТ ЛИМИТЕД (GB) , где Y1 и Y2 независимо представляют собой CH2 или O; X1 и X2 независимо представляют собой S или O; R1 представляет собой OH, и R2 представляет собой NH2, или R1 представляет собой NH2, и R2 представляет собой H; R3 представляет собой OH, и R4 представляет собой NH2, или R3 представляет собой Стр.: 1 NH2, и R4 представляет собой H; R5 выбирают из: F, OH и OC(O)R7; R6 выбирают из: F, OH и OC(O)R7; при условии: если ни R5, ни R6 не представляют собой F, то, по меньшей мере, один из Y1 и Y2 представляет собой CH2; и R8 и R9 независимо выбирают из: H, CH2OC(O)R7, CH2OCO2R7, CH2CH2SC(O)R7 и CH2CH2SSCH2R7; при условии: если X1 и X2 оба представляют собой O, то, по меньшей мере, один из R8 и R9 не представляет собой H; R U где R7 выбирают из: арила, гетероарила, гетероциклоалкила, циклоалкила, C1-20алкила и C1-20алкила, замещенного 1-5 заместителями, независимо выбранными из: арила, циклоалкила, гидрокси и F; или его фармацевтически приемлемая соль. R U A 2 0 2 0 1 1 3 1 6 5 A 2 0 2 0 1 1 3 1 6 5 Стр.: 2

3,9-Diphosphaspiroundecanes and process for making 3,9-diphosphaspiroundecanes

本发明提供了一种制备二磷杂螺十一烷的改进方法和由该方法制备的产品，其中所述的方法包括使羟基取代的有机化合物、三氯化磷和季戊四醇反应形成有机取代的二磷杂螺十一烷，所述的有机取代的二磷杂螺十一烷是在三正烷基胺(其中的每一个正烷基含有至少三个碳原子)存在下形成的。本发明还涉及3，9-二(2，6-二叔烷基-4-烷基苯氧基)-2，4，8，10-四氧杂-3，9-二磷杂螺[5.5]十一烷和含有有效量的该化合物的聚合物组合物。

Diphosphite-based antioxidant material and polymer resin composition including same

디포스파이트계 산화방지제 및 이를 포함하는 고분자 수지 조성물에 관한 것으로서, 상기 산화방지제는 하기 화학식 1로 표현되는 디포스파이트계 산화방지제이다. [화학식 1] The present invention relates to a diphosphite antioxidant and a polymeric resin composition containing the same, wherein the antioxidant is a diphosphite antioxidant represented by the following general formula (1). [Chemical Formula 1]